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 ABSTRACT 
Dopamine is one of the main neurotransmitters in the brain. Dopaminergic 
signalling regulates reward, memory, attention and motor functions. In the 
synapses of dopaminergic neurons, dopamine transporter (DAT) re-uptakes 
dopamine into the presynaptic nerve terminals after dopamine release 
terminating the dopaminergic signal and acting as one of the main regulators 
for kinetics of dopaminergic neurotransmission. Loss of dopaminergic 
neurons in the nigrostriatal pathway and protein aggregates called Lewy 
bodies are the main pathological findings in Parkinson´s disease. Lewy bodies 
are mainly composed of a protein called α-synuclein. The physiological role of 
α-synuclein has remained unclear but it has been suggested that the main 
function is regulation of dopaminergic neurotransmission since α-synuclein 
has been shown to participate in the regulation of dopamine synthesis, 
storage, release, and metabolism. α-synuclein-regulated functions in 
dopaminergic signaling are described in the literature review of this thesis. 
Prolyl oligopeptidase (PREP) is a serine protease that binds to α-synuclein 
and induces its aggregation. PREP inhibitors have beneficial effects in cellular 
and in vivo models of Parkinson´s disease by reducing α-synuclein aggregates 
and oligomers, and improving motor functions. Additionally, PREP inhibitors 
alter striatal dopamine level in mice and rats, and decrease immunoreactive 
DAT in the mouse striatum suggesting that PREP could have an effect on 
dopaminergic function. 
The aim of this study was to characterize the role of PREP in dopaminergic 
signaling and the effect of α-synuclein in PREP-mediated changes of the 
dopaminergic system. In the first study, the effect of PREP and α-synuclein on 
DAT phosphorylation and function was studied in DAT transfected HEK-293 
cells. PREP altered DAT function and dopamine uptake, but the changes were 
not dependent on ERK phosphorylation or PKC activity. α-synclein had an 
effect on DAT phosphorylation in the absence of PREP but this was also 
independent of phosphorylation of ERK indicating that both α-synuclein and 
PREP are able to modulate DAT function via an ERK-independent 
mechanism. 
In the second study, the role of PREP in dopaminergic signaling was 
characterized in the nigrostriatal pathway of mouse. The influence of PREP 
was investigated by comparing the dopaminergic function of PREP knock-out 
mice and wild-type littermates. Lack of PREP elevated extracellular dopamine 
concentration, delayed re-uptake of dopamine, and increased phosphorylation 
of DAT in the mouse striatum indicating that PREP is able to regulate DAT 
function by modulating phosphorylation and localization of DAT. 
The effect of PREP inhibition on dopaminergic function, behavior, and α-
synuclein in a Parkinson´s disease mouse model was investigated in the third 
study. Overexpression of α-synuclein was induced by supranigral 
  
microinjection of AAV-α-synuclein and mice were treated with the PREP 
inhibitor KYP-2047 after the onset of the behavioral symptoms. KYP-2047 
treatment did not restore α-synuclein-induced reduction in striatal dopamine 
but behavioral improvement and reduction in α-synuclein oligomers indicated 
restoration of dopamine release and recycling. 
The aim of the fourth study was to investigate if α-synuclein-induced 
toxicity in the nigrostriatal pathway is dependent on PREP expression. The 
main finding was that α-synuclein toxicity was reduced in the absence of PREP 
and restoration of PREP expression increased toxicity in the behavioral tests. 
However, nigrostriatal dopamine level was not affected suggesting that lack of 
PREP protects dopamine release and recycling from α-synuclein-induced 
toxicity. 
In conclusion, PREP regulates DAT function in cells and in the mouse 
nigrostriatal pathway, but the mechanism is not dependent on ERK and PKC 
activation. Deletion of PREP or PREP inhibition do not have effects on α-
synuclein-induced dopaminergic cell loss, but they are able to restore behavior 
and dopaminergic function in the mouse brain suggesting that PREP 
inhibitors could provide a novel treatment for Parkinson´s disease. 
  
TIIVISTELMÄ 
Dopamiini kuuluu aivojen tärkeimpiin hermovälittäjäaineisiin, ja se säätelee 
mm. tahdonalaisia liikkeitä ja mielihyvää. Parkinsonin taudissa 
dopamiinihermosolut tuhoutuvat nigrostriataaliradaksi kutsutulla 
aivoalueella, mikä aiheuttaa vapinaa ja liikehäiriöitä. Nykyisillä 
hoitomenetelmillä, jotka perustuvat aivojen dopamiinin korvaamiseen, 
voidaan lievittää taudin oireita, mutta ei hidastaa tai pysäyttää sairauden 
etenemistä. Terveissä aivoissa α-synukleiiniksi kutsuttu proteiini osallistuu 
dopamiinin muodostumisen, varastoitumisen, vapautumisen ja hajoamisen 
säätelyyn, mutta Parkinsonin tautia sairastavien aivoissa α-synukleiinista 
muodostuu proteiinikertymiä, jotka ovat haitallisia solujen normaalille 
toiminnalle. Prolyylioligopeptidaasi (PREP) on entsyymi, joka lisää α-
synukleiinikertymien muodostumista, ja aiemmissa tutkimuksissa on 
selvinnyt, että PREP-entsyymin toimintaa estämällä voidaan vähentää α-
synukleiinikertymiä Parkinsonin taudin solu- ja eläinmalleissa. PREP-estäjien 
on myös havaittu aiheuttavan muutoksia dopamiinijärjestelmän toimintaan 
aivojen nigrostriataaliradassa hiirillä ja rotilla. 
Tämän väitöskirjatyön tarkoituksena oli tutkia tarkemmin PREP:n roolia 
aivojen nigrostriataaliradan dopamiinijärjestelmässä. Lisäksi tutkittiin, että 
voidaanko PREP-entsyymin toimintaa estämällä korjata α-synukleiinin 
aiheuttamia hermosoluvaurioita Parkinsonin taudin hiirimallissa ja suojaako 
PREP:n poistaminen hiiriä α-synukleiinin vahingollisilta vaikutuksilta.  
Tärkeimpänä löydöksenä oli PREP:n osallistuminen 
dopamiininkuljettajaproteiinin toiminnan säätelyyn sekä soluissa että hiiren 
aivoissa. Solukokeet kuitenkin osoittivat, että PREP ei säätele 
dopamiininkuljettajaproteiinin toimintaa sen keskeisimpänä pidettyjen 
säätelijöiden kautta. Parkinsonin taudin hiirimallissa PREP-estäjällä saatiin 
korjattua käytösmuutoksia ja dopamiinijärjestelmän toimintaa, vaikka 
hoidolla ei ollutkaan vaikutusta aivojen dopamiinisolutuhoon. Lisäksi 
havaittiin, että PREP:n puuttuminen vähensi α-synukleiinin haitallisia 
vaikutuksia hiirillä. Yhteenvetona näiden löydösten perusteella voidaan 
todeta, että PREP osallistuu aivojen dopamiinijärjestelmän säätelyyn, ja että 
PREP-estäjät ovat lupaava uusi keino Parkinsonin taudin hoitoon. 
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1 INTRODUCTION 
Dopamine (DA) is one of the main neurotransmitters in the brain. It is a 
chemical messenger involved in reward (Schultz 1998), motivation (Salamone 
& Correa 2012), memory (Luciana et al. 1998), attention (Nieoullon 2002), 
and motor functions (Matsumoto et al. 1999, Hikosaka et al. 2002). There are 
several DAergic pathways in the brain, but this thesis focuses on the 
nigrostriatal pathway which has a central role in Parkinson´s disease (PD) 
pathology (Ehringer & Hornykiewicz 1960). PD is a neurodegenerative disease 
that has resting tremor, slowness of movements, and rigidity as typical motor 
symptoms (Kalia & Lang 2015). The main pathological findings in PD are loss 
of DAergic neurons in the nigrostriatal tract and protein aggregates called 
Lewy bodies. Alpha-synuclein (aSyn) is the main component in Lewy bodies 
(Spillantini et al. 1997). The physiological role of aSyn has remained unclear, 
but modulation of DAergic neurotransmission has been suggested as the main 
role for aSyn since aSyn has been shown to participate in regulation of DAergic 
function by modulating synthesis, storage, release and re-uptake of DA (Butler 
et al. 2017). Dysfunction of these mechanisms could possibly mediate DAergic 
cell loss in PD. The literature review in this thesis will focus on the interplay 
between aSyn and DAergic neurotransmission. 
aSyn has a monomeric or tetrameric form in native conditions (Eliezer et 
al. 2001), but as an intrinsically disordered protein aSyn is prone to misfolding 
and aggregation, and there are numerous studies showing that aSyn oligomers 
or fibrils are toxic and they are able to induce DAergic cell loss in PD (Pieri et 
al. 2016, Conway et al. 1998, Tsigelny et al. 2012). PD is idiopathic in most of 
the cases but there are several PD-linked gene mutations in aSyn coding SNCA 
gene, such as duplication or triplications (Polymeropoulos et al. 1997, 
Singleton et al. 2003, Chartier-Harlin et al. 2004) and several known point 
mutations that predispose people to PD. These gene mutations induce 
formation of toxic forms of aSyn and they have also been used in preclinical 
PD models. There are also other PD linked gene mutations in several different 
genes such as leucine-rich repeat serine/ threonine- protein kinase 2 (LRRK2), 
glucocerebrosidase (GBA), vacuolar protein sorting-associated protein 35 
(VPS35), PTEN-induced putative kinase 1 (PINK1), Parkin, and DJ-1 amongst 
many others (Kalia & Lang 2015).  
Prolyl oligopeptidase (PREP) is a highly conserved serine protease 
(Venäläinen et al. 2004, Kaushik & Sowdhamini 2014) that accelerates the 
aggregation of aSyn (Brandt et al. 2008). PREP inhibitors have shown 
beneficial effects by reducing aSyn aggregates and toxic oligomers, and 
enhancing motor functions in Parkinson´s disease models (Savolainen et al. 
2014, Myöhänen et al. 2012, Dokleja et al. 2014). PREP is also involved in 
regulation of the nigrostriatal DAergic neurotransmission (Jalkanen et al. 
2012, Savolainen et al. 2014), and it has been shown that PREP inhibitors are 
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able to alter nigrostriatal DA level and DAT immunoreactivity in mice and rats 
(Jalkanen et al. 2012, Savolainen et al. 2014). The role of PREP in the 
regulation of the nigrostriatal DAergic system and DAT function was studied 
further in the results part of this thesis. The interplay between PREP, aSyn, 
and DAT was also studied to investigate if aSyn-induced changes in DAT 
function can be modulated by PREP. 
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2 REVIEW OF THE LITERATURE 
2.1 OVERVIEW OF BRAIN DOPAMINERGIC SYSTEM 
DA was first synthesized in 1910 (Barger & Dale 1910) and its neurotransmitter 
properties and localization in the brain were found in 1957 (Carlsson et al. 
1957, Montagu 1957, Carlsson et al. 1958). Subsequent studies have shown 
that DA is one of the main neurotransmitters. The main pathways are the 
nigrostriatal pathway, mesocortical pathway, mesolimbic pathway, and 
tuberoinfundibular pathway (Figure 1). This thesis review mainly focuses on 
the nigrostriatal pathway which controls movements and motor skill learning. 
In this pathway, the DAergic cell bodies are located in the substantia nigra 
(SN) and projecting to the dorsal striatum (STR). Loss of nigrostriatal DAergic 
neurons is one of the main pathological finding in Parkinson´s disease (PD), 
and the main reason for the motor symptoms of the disease. Impaired DAergic 
signaling is also involved in several other neurological diseases such as 
Huntington´s disease, schizophrenia, attention deficit/hyperactivity disorder 
(ADHD) and psychostimulant drug addiction. 
 
 
Figure 1 DAergic pathways in the brain. Adapted by permission from Springer Nature: Cellular 
and Molecular Neurobiology, Dopamine: Functions, Signaling, and Association with 
Neurological Diseases, Klein M. O., Battagello D. S., Cardoso A. R. et al, Vol 39, pages 31-
59, copyright (2018). 
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2.1.1 DOPAMINE SYNTHESIS AND METABOLISM 
The precursor for DA, tyrosine, is coming from ingested protein 
(Fernstrom & Fernstrom 2007). Substantial biosynthesis of DA also happens 
outside the brain by mesenteric organs (Eisenhofer et al. 1997), but this review 
focuses on DA synthesis and metabolism in the central nervous system. The 
classical pathway for DA biosynthesis was found in 1939 (Blaschko 1939). DA 
is synthesized in the cytosol of catecholaminergic cells in the brain where 
tyrosine hydroxylase (TH), the rate limiting enzyme in DA synthesis, converts 
tyrosine to levodopa using tetrahydrobiopterin, oxygen (O2), and iron (Fe2+) 
as cofactors (Nagatsu et al. 1964). TH is widely used as a marker for DAergic 
cells in brain research since it is mainly localized in the catecholaminergic cells 
(Weihe et al. 2006). Aromatic amino acid decarboxylase (AADC) converts 
levodopa to DA having pyridoxal phosphate as a cofactor (Christenson et al. 
1970). In addition to the main synthesis pathway, DA can be synthesized by a 
cytochrome P450-mediated pathway, but the contribution to the total DA 
synthesis is low in normal conditions (Hiroi et al. 1998, Bromek et al. 2011, 
Bromek et al. 2010). 
After synthesis, DA is stored in presynaptic vesicles by vesicular 
monoamine transporter 2 (VMAT2) in the DAergic cells or it is further 
converted to adrenaline and noradrenaline in adrenergic and noradrenergic 
cells (Eiden & Weihe 2011, Udenfriend & Wyngaarden 1956, Weinshilboum et 
al. 1971). DA is sensitive to oxidation in a non-acidic environment, but VMAT2 
protects neurons from oxidative stress by storing DA in the acidic vesicles 
(Guillot & Miller 2009). Excitation of DAergic neurons leads to release of DA 
into the synaptic cleft from the presynaptic vesicles by exocytosis. Thereafter, 
DA can interact with postsynaptic DA receptors or regulatory presynaptic DA 
autoreceptors. DAergic signaling ends when extracellular DA is removed from 
the synaptic cleft by reuptake of DA to the presynaptic nerve terminals or by 
degradation in the glial cells (Meiser et al. 2013). VMAT2 recycles DA to 
vesicles but excess DA, accumulating to the cytosol, is degraded by monoamine 
oxidase (MAO) to hydrogen peroxide and to the reactive 3,4-
dihydroxyphenylacetaldehyde (DOPAL). DOPAL is preferentially converted to 
3, 4-dihydroxyphenylacetic acid (DOPAC) by the enzymes aldehyde 
dehydrogenase (ALDH) or alcohol dehydrogenase (ADH). DA is also taken 
into the glial cells from the synaptic cleft and degraded by MAO or by catechol-
O-methyl transferase (COMT). COMT transfers DA into 3-methoxytyramine 
and it is also able to degrade DOPAC further into homovanillic acid (HVA). DA 
and its metabolites are then conjugated with sulphates and glucuronides 
before they are excreted to urine (Buu et al. 1981, Uutela et al. 2008).  
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Figure 2 DA synthesis and metabolism. In the main synthesis pathway, L-phenylalanine is 
converted to L-tyrosine and further to levodopa by the rate limiting enzyme, TH. AADC converts 
levodopa to DA. DA is metabolized to 3-methoxytyramine by COMT and to DOPAL by MAO in 
the main metabolic pathways. 3-methoxytyramine is degraded further to HVA by MAO and 
ALDH. DOPAL is metabolized to DOPAC by ALDH or to DOPET by ADH. The main 
metabolites, DOPAC and HVA, undergo glucuronidation or sulphatation reaction, but DA can 
also be directly glucuronized or sulphatized. In noradrenergic and adrenergic cells, DA can be 
converted to norepinephrine and further to epinephrine. Adapted by permission from BioMed 
Central Ltd: Complexity of dopamine metabolism, Meiser J., Weindl D., Hiller K. Vol 11, 
copyright (2013). 
In the brain, MAO is localized in neurons, astrocytes, and glial cells, but 
presence of MAO is low in the nigrostriatal neurons compared to other 
neurons (Westlund et al. 1988). MAO has two isoforms: MAO-A and MAO-B 
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(Bach et al. 1988, Johnston 1968). Both isoforms are localized on the outer 
mitochondrial membrane, but they have differences in affinity to DA in vivo; 
in humans DA is oxidized mainly by MAO-B but in rats by MAO-A (Napolitano 
et al. 1995). COMT is present only in the glial cells in the nigrostriatal tract 
(Myöhänen et al. 2010). DA synthesis and metabolism pathways are presented 
in Figure 2 and neuronal localization of synthesis and metabolism phases is 
presented in Figure 3. 
2.1.2 DOPAMINE STORAGE AND RELEASE 
 
Presynaptic vesicles are formed from plasma membrane by endocytosis. After 
the DA synthesis or reuptake of DA, VMAT2 transfers DA from cytosol into 
synaptic vesicles where it is stored until action potential signal induces fusion 
of the vesicles to the presynaptic membrane releasing DA to the synaptic cleft 
by exocytosis (Fon et al. 1997, Guillot & Miller 2009) (Figure 3). Influx of 
extracellular calcium (Ca2+) causes fast release of neurotransmitters in less 
than 1 ms after the Ca2+ influx (Jahn & Scheller 2006, Martens & McMahon 
2008). DA containing vesicles are transferred to the plasma membrane by 
motor proteins and vesicles interact with soluble N-ethylmaleimide-sensitive 
factor-attached receptor (SNARE) complex proteins that dock and then prime 
vesicles for membrane fusion (Li & Chin 2003). 
2.1.2.1 Vesicular monoamine transporter (VMAT) 
The main function for VMATs is packaging DA and other neurotransmitters 
from cytoplasm into synaptic vesicles. They are members of the solute carrier 
(SLC) protein family. The VMAT2 isoform is expressed mostly in neuronal 
cells in the brain, while isoform VMAT1 is expressed in neuroendocrine cells 
in the periphery (Erickson et al. 1996, Henry et al. 1994). VMAT2 is localized 
principally in small vesicles close to presynaptic membranes in the striatal 
axons and nerve terminals (Nirenberg et al. 1995, Nirenberg et al. 1997b, 
Nirenberg et al. 1997a). VMAT2 is a stoichiometric antitransporter that 
transfers two H+ ions out of the vesicle while transporting one monoamine 
molecule into the vesicle (Knoth et al. 1981, Johnson et al. 1981). In the 
DAergic cells, VMAT2 regulates neurotransmission but also protects cells 
from the toxicity of DA and its metabolites since DA is not degraded in the 
acidic lumen of the vesicle as easily as in the non-acidic environment in the 
cytosol (Caudle et al. 2007, Guillot & Miller 2009, Kariya et al. 2005). VMAT2 
is able to modulate DA release by controlling DA concentration in the synaptic 
vesicles, and thus is regulating the amount of DA released in the synapse 
(Colliver et al. 2000). Increase in cytosolic DA level or increase in VMAT2 
expression are both able to increase the DA release by elevating the DA 
concentration in the vesicles (Pothos et al. 1996, Pothos et al. 2000). 
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Activation of DA receptor D2 increases VMAT2 function and induces 
redistribution of VMAT2 in striatal synaptosomes (Truong et al. 2004). 
2.1.2.2 Soluble N-ethylmaleimide-sensitive factor-attached receptor 
(SNARE) complex 
SNARE proteins compose a fundamental proportion of more than 50 proteins 
that are involved in neurotransmitter release. SNARE proteins are classified 
into two groups: vesicle-SNAREs that are bound to synaptic vesicles, i.e. 
vesicle-associated membrane protein 2 (VAMP2) also known as 
synaptobrevin, and the target-SNAREs, i.e. synaptosomal nerve-associated 
protein 25 kDa (SNAP-25) and syntaxin-1, that are enriched in lipid rafts and 
bound to the presynaptic membrane (Chamberlain et al. 2001, Wickner & 
Schekman 2008).  VAMP2, SNAP-25, and syntaxin-1 are essential for normal 
neurotransmitter release (Jahn & Scheller 2006, Jones et al. 2001, Cervinski 
et al. 2010, Schoch et al. 2001, Sørensen et al. 2003). Assembly of vesicle-
SNAREs and target-SNAREs leads to formation of a highly stable four-helix 
bundle called the SNARE complex which brings synaptic vesicle membrane 
and presynaptic membrane to close proximity and induces fusion of the 
membranes leading to DA release to the synaptic cleft by exocytosis (Söllner 
et al. 1993). 
DA is able to promote SNARE-complex formation (Fisher & Braun 2000). 
Protein kinase C (PKC) has been suggested to regulate DA storage and release 
since PKC activator PMA increases plasma membrane localization of DA 
containing vesicles and enhances depolarization-induced DA release in PC12 
cells (Shoji‐Kasai et al. 2002). 
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Figure 3 Neuronal DA metabolism. DA is synthesized in the presynaptic DAergic neuron and 
stored in the synaptic vesicles.  DA is released from the vesicles by exocytosis to the synaptic 
cleft where it can interact with DA receptors. After the release, DA is removed from the synaptic 
cleft by diffusion and by active transportation by DAT. In the presynaptic cells, DA is recycled 
or degraded by MAO, and in the glial cells degraded by COMT and MAO. Adapted by 
permission from BioMed Central Ltd: Complexity of dopamine metabolism, Meiser J., Weindl 
D., Hiller K. Vol 11, copyright (2013). 
2.1.3 DOPAMINE TRANSPORTER 
DAT is a highly conserved presynaptic membrane protein (Amara et al. 
1997, Nirenberg et al. 1996) that is essential in terminating DAergic signaling 
by removing DA from the synaptic cleft to the presynaptic neuron. DA is 
removed from the synaptic cleft mostly by diffusion after DA release, but DAT 
is the main regulator of the kinetics of extracellular DA (Rice & Cragg 2008). 
DAT belongs to the SLC6 transporter family of sodium/chloride (Na+/Cl−)-
dependent neurotransmitter transporters (Ramamoorthy et al. 2011). It is 
composed of 12 transmembrane segments that form the core of the substrate 
translocation pathway and large N- and C-terminal domains that are oriented 
toward the cytoplasm (Giros et al. 1992). These terminals are the primary 
regions for post-translational modifications and for protein-protein 
interactions regulating DAT function. DAT transports DA against its 
concentration gradient by co-transport of Na+ and Cl- along their 
concentration gradients. DAT is primarily expressed on the plasma membrane 
where it can interact with extracellular DA.  
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DAT function is regulated by post-translational modifications, protein-
protein interactions and internalization (German et al. 2015). 
Phosphorylation, ubiquination, glycosylation, palmitoylation, oxidation, and 
nitrosylation are able to modulate DAT function by changing DAT interactions 
with other molecules, regulating localization of DAT or altering DAT transport 
kinetics. Transport capacity of DAT can be modulated acutely as a 
physiological response to a variety of conditions and signaling, and 
dysfunction in these functions can have an important role in the pathogenesis 
of several neurological diseases (German et al. 2015, Foster & Vaughan 2017). 
Pharmacological modulation of post-translational modifications can provide 
numerous targets for treatment of DAT-related neurological diseases. 
There are several kinases and other molecules that have long term effects 
on DAT function. The most studied kinases regulating DAT function are 
protein kinase C (PKC) (Vaughan et al. 1997), calcium-calmodulin dependent 
kinase II (CAMKII) (Fog et al. 2006), and extracellular signal-regulated 
protein (ERK) (Vaughan & Foster 2013, German et al. 2015, Foster & Vaughan 
2017), but there are also some studies indicating a regulatory role for protein 
kinase A (PKA) (Batchelor & Schenk 1998), mitogen-activated protein kinase 
(MAPK) (Morón et al. 2003), tyrosine kinases (Hoover et al. 2007), 
arachidonic acid (Chen et al. 2003), Akt (Speed et al. 2010), phosphatidyl 
inositol 3-kinase (Carvelli et al. 2002), nitric oxide (Pogun et al. 1994), protein 
phosphatase 2A (PP2A) (Yang et al. 2018). Additionally, DA receptors D2 (Lee 
et al. 2007), and D3 (Zapata et al. 2007) can act as autoreceptors and regulate 
DAT function. Also, psychostimulants are able to modulate DAT function by 
several mechanisms. 
Internalization is the main regulatory mechanism for DAT transport 
capacity, and phosphorylation of DAT regulates internalization (Melikian & 
Buckley 1999, Vaughan et al. 1997, Daniels & Amara 1999). Phosphorylation 
sites are located in the intracellular N- and C-terminals of DAT. 
Phosphorylation of Thr53 site in the MAPK/SH3 domain stabilizes DAT on the 
plasma membrane (Morón et al. 2003) while phosphorylation of Ser7 and 
Ser13 in the PKC domain induce internalization of DAT (Vaughan et al. 1997, 
Foster & Vaughan 2017) (Figure 4). 
2.1.3.1 Protein kinase C 
PKC-mediated phosphorylation of DAT has been suggested as one of the main 
regulators for DAT function (Vaughan et al. 1997). It was first shown that PKC 
activators can decrease DA uptake in striatal synaptosomes (Copeland et al. 
1996). PKC induces phosphorylation of Ser7 and Ser13 in the PKC domain in 
the N-terminal of DAT leading to internalization of phosphorylated DAT 
(Loder & Melikian 2003, Vaughan et al. 1997, Pristupa et al. 1998, Karam et 
al. 2017). Internalization decreases DAT on the plasma membrane and leads 
to downregulation of the transport capacity. PKC also activates ERK, and thus 
is also able to modulate MAPK/SH3 domain phosphorylation. 
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2.1.3.2 Extracellular signal-regulated kinase 
ERK is a negative regulator for DA signaling (Bolan et al. 2007). 
Phosphorylation activates ERK and leads to phosphorylation of the Thr53 site 
in the MAPK/SH3 domain located in the N-terminal of DAT (Morón et al. 
2003, Challasivakanaka et al. 2017, Foster et al. 2012). This induces 
upregulation of DAT on the plasma membrane and increases transport 
capacity leading to decreased extracellular DA.  Amphetamines elevate ERK 
activity, and ERK inhibition is able to block their effect showing that their 
effect is dependent on ERK-mediated phosphorylation of DAT (Foster et al. 
2012, Shi & McGinty 2006).  
2.1.3.3 Calcium-Calmodulin dependent kinase II 
CaMKII is a cellular target for Ca2+ which colocalizes and interacts with 
DAT (Fog et al. 2006, Steinkellner et al. 2012). CaMKII phosphorylates serines 
in the C-terminal and induces DA efflux. Amphetamine-induced DA efflux is 
also dependent on CaMKII (Fog et al. 2006, Steinkellner et al. 2014, 
Steinkellner et al. 2012). 
2.1.3.4 Psychostimulants 
Psychostimulants, such as methamphetamine, amphetamine and cocaine, are 
also able to modulate DAT function, and they have been widely used for 
preclinical research of DAergic function. Methamphetamine and 
amphetamine regulate localization of DAT and they are also able to reverse DA 
transport from the cytosol (Sulzer 2011, Gulley & Zahniser 2003). Acute 
administration of cocaine blocks DAT transport, while chronic administration 
upregulates DAT function (Volkow et al. 1997, Mash et al. 2002). 
Amphetamines induce internalization of DAT even though they phosphorylate 
the Thr53 site in the N-terminal, while cocaine does not have a similar 
mechanism (Cervinski et al. 2005, Saunders et al. 2000, Challasivakanaka et 
al. 2017). Amphetamine- and methamphetamine-mediated phosphorylation 
and internalization are dependent on PKC activity (Cervinski et al. 2005, 
Richards & Zahniser 2009). Amphetamines also increase cytosolic DA by 
activating TH, inhibiting MAO, and impairing VMAT2 function (Sulzer 2011). 
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Figure 4 Phosphorylation of DAT. DAT has 12 transmembrane helices that form the core of 
the substrate translocation pathway, and large C- and N-terminals pointing toward the 
cytoplasm. The most important N-terminal located phosphorylation sites Thr53 in MAPK/SH3 
binding domain, and Ser7 and Ser13 in PKC binding domain are marked with large blue circles. 
C-terminal located CaMKII binding domain is marked with green circles. Journal of chemical 
neuroanatomy, Vol 83, Foster, J. D. and Vaughan, R. A., Phosphorylation mechanisms in 
dopamine transporter regulation., pages 10-18., copyright (2017), with permission from 
Elsevier. 
2.1.4 DOPAMINE RECEPTORS 
After release, DA can bind to DA receptors located on the presynaptic or 
postsynaptic membrane. DA receptors are categorized as D1 like receptors, 
which includes receptors D1 and D5, and D2 like receptors, which includes 
receptors D2, D3 and D4 (Baik 2013, Klein et al. 2018). All DA receptors are 
metabotropic that act through a second messenger that modulates specific 
signaling pathways. D1 like receptors are located in the postsynaptic 
membranes mostly in the STR, SN, nucleus accumbens, olfactory bulb, 
amygdala, and frontal cortex (Savasta et al. 1986, Baik 2013, Wamsley et al. 
1989). D2 and D3 receptors are located in both presynaptic and postsynaptic 
membranes, and found mainly in the STR, globus pallidus, nucleus 
accumbens, ventral tegmental area, hypothalamus, amygdala, cortical areas, 
hippocampus, and pituitary (Wamsley et al. 1989, Yokoyama et al. 1994, Baik 
2013). D4 receptors are expressed mostly in retina (Cohen et al. 1992). D1 like 
receptors have lower affinity to DA than D2 like receptors (Baik 2013, Klein et 
al. 2018). D1 like receptors are suggested to be preferentially activated by high 
concentrations of DA phasic release, while D2 like receptors would detect tonic 
low levels of DA. 
Presynaptically located DA receptor D2 and D3 act as autoreceptors 
regulating DA release (Beaulieu & Gainetdinov 2011). Activation of 
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presynaptic DA receptor D2 decreases DA release. DA receptor D2 promotes 
plasma membrane localization of DAT via direct protein-protein interaction 
leading to enhanced DA uptake (Lee et al. 2007) but DA receptor D2 also 
regulates DAT function via ERK1/2 (Bolan et al. 2007). Disruption of DAT and 
DA receptor D2 interaction has a neuroprotective effect (Su & Liu 2017). DA 
receptor D3 is also able to modify DAT function by activating phosphatidyl 
inositol 3 and MAPK (Zapata et al. 2007, Zapata & Shippenberg 2002). 
2.2 OVERVIEW OF α-SYNUCLEIN 
aSyn is a small,  140 amino acid protein encoded by SNCA gene, and is a 
member of synuclein family that includes also β-synuclein and γ-synuclein 
(Clayton & George 1998, Polymeropoulos et al. 1997). aSyn is widely expressed 
in the brain but is highly concentrated into the presynaptic nerve terminals 
(Spillantini et al. 1997, Iwai et al. 1995), and there is high expression levels in 
the DAergic brain regions (Taguchi et al. 2016). Survival and relatively normal 
development of aSyn knock-out mice has shown that aSyn is not essential 
(Chandra et al. 2004), but its physiological role is poorly understood, though 
modulation of DAergic neurotransmission has been suggested as its main 
function. aSyn has several protein-protein interactions and protein-lipid 
membrane interactions that are important for synaptic function homeostasis. 
It has been shown to regulate several steps of DAergic neurotransmission that 
are discussed later in this review. aSyn also interacts with a variety of 
cytoskeletal proteins that participate in the maintenance of cell structure and 
protein trafficking (Prots et al. 2013, Alim et al. 2002, Longhena et al. 2019). 
aSyn is able to modulate stability and organization of microtubules (Cartelli et 
al. 2016, Cartelli & Cappelletti 2017) and it affects anterograde axonal 
transport by binding to several proteins including tubulin, microtubule-
associated protein 2, and tau (Prots et al. 2013, Longhena et al. 2019). 
aSyn is mainly in an unfolded monomeric form in native conditions 
(Eliezer et al. 2001), but adopts α-helical conformation on membranes 
(Davidson et al. 1998, Chandra et al. 2003). Monomer and tetramer 
conformations are suggested to be the physiological forms of aSyn, while 
oligomers and fibrils are supposed as pathogenic forms (Bartels et al. 2011, 
Marques & Outeiro 2012). The soluble monomeric, unfolded aSyn and 
multimeric membrane-bound forms are suggested to have equilibrium that 
depends on N-terminal acetylation (Neupane et al. 2014, Bartels et al. 2010). 
2.3 DOPAMINE AND α-SYNUCLEIN IN PARKINSON´S 
DISEASE 
Parkinson´s disease (PD) is the second most common neurodegenerative 
disorder originally described by James Parkinson in 1817 (Parkinson 1817). 
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The motor symptoms tremor, rigidity, and slowness of movements are caused 
by loss of DAergic neurons in the nigrostriatal pathway in the brain (Ehringer 
& Hornykiewicz 1960). Parkinson´s disease is usually diagnosed when 
approximately 30 % of DAergic neurons in the SN and 50-60 % of their axon 
terminals in the STR are lost (Cheng et al. 2010). Neurodegeneration has been 
suggested to start from striatal nerve terminals then progressing later to the 
cell somas in the SN, which can explain wider loss of neurons in the STR 
compared to SN (Hornykiewicz 1998, Bridi & Hirth 2018). Also, reduction of 
immunoreactive DAT has been observed in the STR in PD brains (Miller et al. 
1997). A PET study in early PD patients revealed 36% to 70% decreased 
binding potential of DAT in the presynaptic terminals in the STR and 30 % 
reduction in the cell bodies in the SN (Fazio et al. 2018).  
The reason for DAergic neurodegeneration has remained obscure but 
multiple studies have revealed contribution of oxidative stress in the cell loss 
(Puspita et al. 2017). DA is a highly reactive molecule that can generate 
reactive oxygen species (ROS) such as hydroxyl radical, DA-o-quinone, 
superoxide, and hydrogen peroxide (Graham 1978). ROS are able to react with 
proteins, DNA and lipids, and these oxidatively modified molecules are found 
in the brain of PD patients (Spencer et al. 2002, Good et al. 1998, Alam et al. 
1997). The highly reactive DA metabolite, DOPAL, is even more prone to 
induce oxidative stress than DA (Kristal et al. 2001) and it is toxic to neurons 
in vitro (Goldstein et al. 2012) and in vivo (Burke et al. 2003). DOPAL is 
increased in the PD brain which can be observed as elevated DOPAL:DA and 
DOPAL:DOPAC ratios (Goldstein et al. 2011). This elevation is caused by 
combination of decreased ALDH activity and decreased vesicular uptake of 
cytosolic DA by VMAT2 (Goldstein et al. 2013, Pifl et al. 2014). Loss of DAergic 
cells reduces DA related proteins VMAT2 and DAT in the PD brain, but DA 
uptake by VMAT2 is also reduced after correcting for DA nerve terminal loss 
(Pifl et al. 2014, Miller et al. 1997). Neuroimaging of VMAT2, DAT, and AADC 
with positron emission tomography (PET) or single photon emission 
computed tomography (SPECT) can be used in clinical research of PD 
(Kaasinen & Vahlberg 2017). Reduced VMAT2 has also been observed in the 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-model of PD in non-
human primates (Chen et al. 2008). Intracerebral injection of DOPAL to 
rodents produces behavioral changes and pathology similar to PD showing 
that administration of DOPAL can be used to model PD  and indicating that 
elevated DOPAL can lead to increased oxidative stress, toxicity, and DAergic 
cell loss in PD (Panneton et al. 2010, Burke et al. 2003).  
In addition to DAergic dysfunction and cell loss another main pathological 
finding in the PD brain is protein aggregates called Lewy bodies that are 
mainly composed of aSyn (Spillantini et al. 1997). PD is commonly idiopathic, 
but there are also familial forms of PD. Mutations in various genes have been 
linked to PD including SNCA gene coding aSyn (Singleton et al. 2003, 
Polymeropoulos et al. 1997, Krüger et al. 1998). The most common point 
mutations in the SNCA gene are alanine to threonine substitution at position 
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53 (A53T), and alanine to proline substitution at position 30 (A30P) (Krüger 
et al. 1998, Polymeropoulos et al. 1997). These mutations have been shown to 
accelerate oligomerization and aggregation of aSyn (Conway et al. 2000, 
Conway et al. 1998). Moreover, duplication or triplication of SNCA causes 
familial PD (Chartier-Harlin et al. 2004, Singleton et al. 2003). Also, an A53E-
associated mutation of SNCA gene has been found, which is linked to familial 
PD from Finland (Pasanen et al. 2014, Pasanen et al. 2017). Additionally, 
mutations in PTEN-induced putative kinase 1 (PINK1), Parkin, DJ-1, and 
leucine-rich repeat kinase 2 (LRRK2), among others, are associated to PD 
(Hernandez et al. 2016) but they are not discussed further in this thesis. 
Mutated aSyn or overexpression of aSyn have been widely used to model PD 
in cell cultures and in animals. 
Phosphorylation of serine 129 residue promotes fibrillization of aSyn in 
vitro and this residue is selectively and extensively phosphorylated in 
synucleinopathy lesions (Fujiwara et al. 2002). Increase in ser-129 
phosphorylated aSyn has been found in the cerebrospinal fluid of PD patients 
when total aSyn remained unaltered (Wang et al. 2012). However, 
phosphorylation of aSyn has been shown to decrease neurotoxicity in 
Drosophila (Chen & Feany 2005) and in rats (Gorbatyuk et al. 2008). Ser-192 
phosphorylation also induces degradation of aSyn via autophagic and 
proteasomal pathways (Machiya et al. 2010). 
Current treatments for PD are focused on increasing DA levels in the brain 
or to improve DAergic signaling. The precursor for DA, levodopa, is the golden 
standard in the treatment of motor symptoms of PD (Kalia & Lang 2015). It 
can alleviate symptoms efficiently by elevating DA level in the DAergic 
neurons of the central nervous system, but the efficiency of levodopa 
treatment reduces over time, and levodopa can cause severe side effects such 
as fluctuations and dyskinesia. Levodopa has a short biological half-life but 
COMT inhibitors, such as entacapone and opicapone, are used to inhibit DA 
metabolism and to extend the effect of levodopa. Additionally, MAO-B 
inhibitors, such as selegiline, rasagiline, and safinamide, are used to reinforce 
the effect of levodopa since they reduce DA metabolism and re-uptake, and 
inhibit presynaptic DA receptors. DA agonists, such as pramipexole, 
ropinirole, and rotigotine, can reduce motor symptoms by stimulating D2 and 
D3 receptors. Current medications can alleviate the PD symptoms, but they 
are not able to delay or stop the progression of the disease, thus raising urgent 
need for better understanding of the disease mechanisms and development of 
new treatments to modulate the progression of the disease. 
2.4 Α-SYNUCLEIN AS MODULATOR OF 
DOPAMINERGIC NEUROTRANSMISSION 
aSyn participates in modulation of DAergic neurotransmission by interacting 
with several regulators of DA synthesis, metabolism, storage, release, and 
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clearance. Many of these interactions are altered in PD but their importance 
in the pathogenesis of PD has remained obscure. These interactions are 
discussed in detail below and they are gathered in Table 1. 
2.4.1 DIRECT INTERACTION BETWEEN α-SYNUCLEIN AND 
DOPAMINE 
 
DA is toxic to cultured midbrain neurons but lack of aSyn protects neurons 
from toxicity and cell loss pointing to an interaction between DA and aSyn 
(Mosharov et al. 2009).  DA interacts with aSyn and induces formation and 
accumulation of soluble SDS-resistant aSyn oligomers and inhibits conversion 
of oligomeric aSyn to fibrils in vitro (Cappai et al. 2005, Rochet et al. 2004, 
Conway et al. 2001) and in SH-SY5Y cells (Mazzulli et al. 2006). Oxidation of 
DA is required for the interaction in the cytosol (Mazzulli et al. 2007), but DA 
is quickly oxidized to reactive quinone species, hydrogen peroxide, and other 
electrophiles in the cytosolic pH (Graham 1978). Oxidized DA changes the 
conformation of aSyn leading to a conformation that is suggested to be a 
precursor for the oligomeric form of aSyn (Outeiro et al. 2009, Norris et al. 
2005). Oligomerization of A53T and A30P mutated aSyn is faster than wild-
type aSyn and DA is able to stabilize mutated aSyn oligomers more than wild-
type aSyn oligomers in vitro which can possibly explain the faster progression 
of PD in patients with aSyn mutations (Follmer et al. 2007, Conway et al. 
1998).  Overexpression of mutated A53T aSyn results in no loss of DAergic 
cells in a mouse model of PD (Giasson et al. 2002) but Mor et al. (2017) 
showed that A53T mutated aSyn overexpression combined with elevated DA 
level leads to accumulation of toxic aSyn oligomers and induced progressive 
nigrostriatal degeneration proving that DA and aSyn also interact in vivo. DA-
induced oligomerization of aSyn can possibly provide a link between DA- and 
aSyn-mediated toxicities and explain the selective accumulation of Lewy 
bodies in the DAergic cells and loss of DAergic neurons in PD. 
2.4.2 α-SYNUCLEIN AND DOPAMINE SYNTHESIS 
 
TH, the rate limiting enzyme in DA synthesis, is decreased in the nigrostriatal 
pathway in PD mainly due to loss of TH-positive DAergic neurons, but TH 
might also be decreased in the remaining neurons (Nagatsu & Nagatsu 2016). 
Furthermore, overexpression of wild-type or mutated aSyn induces 
degeneration of TH-positive DAergic neurons in animal models of PD (Kirik 
et al. 2002, Kirik et al. 2003). Perez et al. (2002) showed that aSyn is able to 
bind to TH and inhibit TH activity in vitro. Overexpression of aSyn did not 
have an effect on TH protein level but decreased activity of TH leading to 
decreased DA synthesis (Perez et al. 2002). Silencing of aSyn has an opposite 
effect by increasing TH activity and DA synthesis in DAergic MN9D cells (Liu 
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et al. 2008). Additionally, the amount of immunoreactive TH was elevated in 
aSyn/γ-synuclein double knock-out mouse retinal cells (Surgucheva et al. 
2005), although aggregated aSyn is not able to modulate TH activity (Alerte et 
al. 2008). In addition to direct binding, aSyn regulates TH activity by 
activating protein phosphatase 2A (PP2A) which reduces phosphorylation and 
activity of TH (Hua et al. 2015, Peng et al. 2005). Phosphorylation of aSyn 
reduces its impact on TH and PP2A activity and thus upregulates TH activity 
and DA synthesis (Wu et al. 2011, Lou et al. 2010). In PD, increase in 
aggregated aSyn and decrease in soluble aSyn could increase TH activity 
leading to increased DA synthesis and cellular DA concentration which can 
possibly cause oxidative stress and damage to the cells. 
aSyn also interacts with another substantial enzyme in DA synthesis, AADC 
which converts levodopa to DA, by inhibiting its activity in a DAergic cell line 
(Tehranian et al. 2006). However, the interaction between aSyn and AADC 
and its relevance in DA synthesis and PD has not been studied as extensively 
as the interaction between TH and aSyn. 
2.4.3 α-SYNUCLEIN AND DOPAMINE RELEASE AND STORAGE 
aSyn binds to small phospholipid vesicles containing acidic phospholipids but 
not to vesicles with neutral charge or large vesicles in vitro (Davidson et al. 
1998). Oligomeric aSyn has been shown to permeabilize vesicles in vitro 
indicating that oligomeric aSyn could also damage DA containing vesicles in 
the DAergic nerve terminals and cause leaking of DA to the cytosol (Volles et 
al. 2001). Membrane bound aSyn is preferentially in an α-helical form but 
oligomeric aSyn has a predominantly β-sheet structure (Davidson et al. 1998, 
Volles et al. 2001). aSyn is located in the presynaptic terminals close to 
synaptic vesicles and it has been shown to have interactions with cellular 
membranes in vivo (Kahle et al. 2000, Jo et al. 2000, Jo et al. 2002). Wild-
type aSyn binds to lipid rafts on cellular membranes but the A30P mutation 
disrupts the interaction with lipid rafts and leads to decreased accumulation 
of aSyn in the synaptic terminals (Fortin et al. 2004). Absence of aSyn leads 
to decreased reserve pool of presynaptic vesicles and slower replenishment of 
the docked vesicles indicating that aSyn is needed for normal synaptic function 
(Cabin et al. 2002). There have also been studies showing that overexpression 
of wild-type or A30P mutated aSyn inhibits catecholamine release without 
affecting calcium threshold, vesicular pool or packing of the vesicles (Larsen 
et al. 2006). However, overexpression of aSyn reduced the readily releasable 
pool of vesicles. 
Abeliovich et al. (2000) showed that aSyn deficient mice have intact 
morphology of the brain and nigrostriatal pathway including DA neurons and 
nerve terminals but the DAergic neurotransmission is altered. DA release and 
reuptake are normal, but recovery of DA release is faster after paired-pulse 
stimulation, DA tissue concentration is lowered and response to amphetamine 
altered indicating that aSyn is able to decrease vesicular storage and is acting 
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as an activity-dependent negative regulator of DA release. Lack of synucleins 
also impairs synaptic vesicle endocytosis, and restoration of mouse aSyn 
expression is able to normalize endocytosis in the mouse brain indicating that 
aSyn is needed for normal synaptic vesicle endocytosis function (Vargas et al. 
2014).  
Overexpression of mutated A30P or A53T aSyn has been shown to elevate 
cytosolic catecholamine concentration in PC12 cells suggesting increased 
leakage of neurotransmitters from storage vesicles (Mosharov et al. 2006). 
Mice lacking aSyn or overexpressing A30P mutated aSyn have a lower capacity 
of the DA storage pool (Yavich et al. 2004). (Chadchankar et al. 2011) had 
similar findings of altered DA release in aSyn deficient mice and they also 
found altered DA reuptake. Additionally, overabundant human wild-type aSyn 
is able to decrease neurotransmitter release by inhibiting synaptic vesicle 
reclustering after endocytosis (Nemani et al. 2010, Gaugler et al. 2012). The 
mechanism in aSyn-mediated modulation of synaptic vesicle recycling is 
suggested to be inhibition of phospholipase D2 (PLD2) which leads to reduced 
formation of the vesicles (Jenco et al. 1998, Ahn et al. 2002). Mutated A53T 
aSyn has a greater ability to inhibit PLD2 than wild-type aSyn (Payton et al. 
2004). Lipid-binding is also suggested to stabilize aSyn into its active α-helical 
conformation (Payton et al. 2004). 
aSyn localizes with VMAT2 in Lewy bodies in PD brains (Yamamoto et al. 
2006). aSyn forms complexes with VMAT2 and overexpression of aSyn 
decreases VMAT2 expression in SH-SY5Y cells leading to decreased VMAT2 
function and elevated intracellular ROS level (Guo et al. 2008). 
Overexpression of A53T mutated aSyn decreases VMAT2 protein level and 
VMAT2-mediated uptake of DA in cells (Lotharius & Brundin 2002). 
Overexpression of VMAT2 protects from levodopa-induced toxicity 
(Mosharov et al. 2009), while reduction of VMAT2 increases oxidative stress, 
DAergic neurodegeneration, and accumulation of aSyn in the SN of aged 
VMAT2 deficient mice (Caudle et al. 2007). Additionally, VMAT2 deficiency 
combined with aSyn overexpression increases cytosolic DA concentration and 
leads to DAergic neurodegeneration in mice (Ulusoy et al. 2012). 
aSyn colocalizes with SNARE proteins, syntaxin-1 and SNAP-25, and age-
dependent redistribution of SNARE proteins and reduction of DA release was 
observed in aSyn transgenic mice (Garcia-Reitböck et al. 2010, Almandoz-Gil 
et al. 2018). aSyn aggregates have been shown to reduce VAMP2 and SNAP-
25 in cells and in mouse brain, while monomeric aSyn did not a have similar 
effect (Choi et al. 2018). There has also been opposite results showing that 
aSyn binding to VAMP2 promotes SNARE-complex assembly by increasing 
clustering of vesicles but overexpression of aSyn still decreased the releasable 
pool (Burré et al. 2010, Diao et al. 2013). α-, β- and γ-synuclein triple knock-
out mice have been shown to develop age-dependent neurological impairment 
and decreased SNARE-complex assembly indicating that synucleins have an 
important role in the regulation of SNARE-complex assembly during aging. 
Monomeric cytosolic aSyn does not promote SNARE-complex assembly but 
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the multimeric membrane-bound form of aSyn is able to mediate SNARE-
complex assembly in the presynaptic nerve terminals (Choi et al. 2013, Burré 
et al. 2014). Large aSyn oligomers have the opposite effect as they inhibit 
SNARE-mediated lipid mixing by preventing SNARE-complex formation 
(Choi et al. 2013). aSyn concentration might also affect the interaction with 
SNARE-complex since low concentrations (<2.5 µM) promoted vesicle 
docking and high concentrations (>4 µM) inhibited docking in the study by 
(Lou et al. 2017). A suggested mechanism for promotion of SNARE-complex 
assembly is aSyn interaction with proteoliposomes in both synaptic and vesicle 
SNARE which could cross-bridge the membranes and promote their fusion 
(Lou et al. 2017). According to variable results, the effect of aSyn on the 
SNARE-complex is dependent on the conformation and concentration of 
aSyn. Furthermore, inhibition of SNARE-complex assembly by aSyn 
oligomers could possibly explain the toxicity of the oligomers. 
2.4.4 α-SYNUCLEIN AND DOPAMINE METABOLITES 
DOPAC, one of the main metabolites of DA, is able to bind to aSyn at low 
concentrations and prevent fibrillization of aSyn by stabilizing it on the 
monomeric form in vitro (Zhou et al. 2009). Interestingly, aSyn induces 
spontaneous oxidation of DOPAC, and the oxidation produces H2O2 which can 
cause oxidation of methionine groups of aSyn leading to formation of soluble 
oligomers and inhibition of fibrillization (Zhou et al. 2009). Additionally, the 
interaction between aSyn and DOPAC decreases binding affinity of aSyn to 
lipids suggesting that DOPAC can inhibit normal function of aSyn and increase 
the toxicity of aSyn aggregates (Zhou et al. 2010). 
The toxic metabolite of DA, DOPAL, induces aggregation of aSyn both in 
vitro and in vivo (Burke et al. 2008) and aSyn oligomerization in vitro and in 
cells (Plotegher et al. 2017, Jinsmaa et al. 2016). DOPAL injection in the rat 
SN causes accumulation of high molecular weight oligomers of aSyn 
suggesting that DOPAL can cause the aSyn aggregation and DAergic cell loss 
observed in PD (Burke et al. 2008). Elevated DOPAL in the PD brain also 
supports this theory (Goldstein et al. 2013, Goldstein et al. 2011). DOPAL is 
shown to stabilize aSyn oligomers by formation of covalent adducts with lysine 
residues of aSyn (Follmer et al. 2015), and ROS produced by DOPAL are able 
to oxidize methionine residues of aSyn and therefore stabilize large aSyn 
oligomers (Follmer et al. 2015, Plotegher et al. 2017, Carmo-Gonçalves et al. 
2018). Decrease in vesicular uptake of cytosolic DA and decrease in 
detoxification of DOPAL by ALDH are suggested to be the main reasons for 
elevated DOPAL in the PD brain (Goldstein et al. 2013). DOPAL-modified 
aSyn also damages cellular vesicles and DOPAL affects the synaptic vesicle 
pool (Plotegher et al. 2017). aSyn-DOPAL oligomers are able to permeabilize 
vesicles when membranes contain cholesterol in vitro suggesting that aSyn-
DOPAL oligomers could possibly cause DA release from the vesicles to cytosol 
leading to oxidative stress and damage to the cells (Plotegher et al. 2017). 
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Overexpression of mutant A53T-aSyn causes transcriptional 
downregulation of COMT in transgenic mice leading to elevated striatal DA 
level but the downregulation of COMT might be a compensation for decreased 
extracellular DA level rather than direct interaction between aSyn and COMT 
(Kurz et al. 2010). Wild-type and mutated aSyn bind directly to another DA 
metabolizing enzyme, monoamine oxidase B (MAO-B), but not MAO-A, and 
aSyn stimulates MAO-B enzymatic activity (Kang et al. 2018) which could lead 
to increased accumulation of DOPAL and elevated oxidative stress. 
2.4.5 α-SYNUCLEIN AND DOPAMINE TRANSPORTER 
SiRNA knock-down of aSyn in a human neuronal cell line decreases DAT 
function and cell surface localization suggesting that endogenous aSyn 
promotes DAT activity and normal function of aSyn includes regulation of 
DAT activity (Fountaine & Wade‐Martins 2007, Fountaine et al. 2008). 
However, altered DAT function has not been observed in aSyn knock-out mice 
(Chandra et al. 2004, Dauer et al. 2002). Impaired regulation of DAT by aSyn 
can lead to changes in extracellular and intracellular DA levels, and cellular 
damage and toxicity (Wersinger et al. 2003b). aSyn binds directly to DAT and 
forms a complex with DAT through binding of the non-Aβ component of aSyn 
and C-terminal tail of DAT (Lee et al. 2001, Wersinger & Sidhu 2003). DAT-
aSyn complexes are located mainly on the plasma membrane indicating that 
aSyn is able to modulate DAT function by stabilizing it on the plasma 
membrane, and amphetamine is able to enhance the association between DAT 
and aSyn at the plasma membrane (Butler et al. 2015). aSyn-DAT complexes 
are also redistributed in the somatodendritic compartment in aSyn transgenic 
mice (Bellucci et al. 2011) suggesting aSyn-mediated modulation of 
somatodendritic DA release which can be substantial in motor functions 
(Hersch et al. 1997). Redistribution of aSyn-DAT complexes has also been 
observed in the caudate putamen of PD patients (Longhena et al. 2018). Both 
wild-type and mutated aSyn are able to form complexes with DAT but A53T 
has a weaker association with DAT than A30P or wild-type aSyn and it is not 
able to decrease DA-induced oxidative stress like A30P and wild-type aSyn 
(Wersinger et al. 2003a). 
However, there are several studies reporting an aSyn-mediated decrease in 
DAT trafficking (Oaks et al. 2013, Wersinger & Sidhu 2003, Kisos et al. 2014, 
Wersinger et al. 2003b, Swant et al. 2011, Pelkonen et al. 2013) suggesting 
that aSyn is able to increase endocytosis of DAT by a chlatrin-dependent 
mechanism (Kisos et al. 2014) and to impair endoplasmic reticulum-Golgi 
transition leading to limited export of DAT from the endoplasmic reticulum 
(Oaks et al. 2013). A study by (Swant et al. 2011) suggests that aSyn can 
decrease DAT activity without changing the amount of DAT on the plasma 
membrane by altering the ionic coupling of DAT leading to decreased DA 
uptake. Wersinger & Sidhu (2003) showed that in its normal state, aSyn is a 
negative regulator for DAT function, and overexpression of aSyn can decrease 
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DAT function in an expression level-dependent manner but 1-Methyl-4-
phenylpyridinium (MPP+)-induced toxicity ablated the aSyn-mediated 
inhibition of DAT activity in cells (Wersinger et al. 2003b). Overexpression of 
aSyn has shown to increase basal and amphetamine-induced DA efflux at 
resting membrane potential (Wersinger & Sidhu 2003). Controversial results 
suggest that the negative or positive impact on DAT trafficking by aSyn 
depends on the circumstances. 
In addition to direct binding, aSyn can interact with DAT by tethering it to 
the microtubular network and decreasing cell surface-associated DAT, and 
microtubule destabilizing agents are able to reverse aSyn-mediated inhibition 
of DAT activity (Wersinger & Sidhu 2005). aSyn also binds to PKC and inhibits 
its activity (Ostrerova et al. 1999) suggesting that aSyn could decrease 
phosphorylation of DAT via PKC and thus enhance internalization of DAT 
(Huff et al. 1997, Vaughan & Foster 2013, Copeland et al. 1996). Another 
protein kinase, PKA, also regulates DAT function but aSyn does not have an 
effect on PKA (Peng et al. 2005). Since PP2A regulates DAT by modulating its 
phosphorylation (Yang et al. 2018, Bauman et al. 2000) aSyn could possibly 
regulate DAT function by increasing PP2A activity (Peng et al. 2005). DA 
receptor D2 is upregulated in the STR of aged A53T-aSyn overexpressing mice 
(Kurz et al. 2010) which may modulate DAT function as DA receptor D2 
stabilizes DAT on the plasma membrane but DA receptor D2 upregulation is 
more likely a result of compensation to decreased DA level (Seeman & Niznik 
1990) than direct interaction between aSyn and DA receptor D2. 
Taken together, aSyn has interactions with several regulators of DAT 
function and it also directly binds to DAT suggesting many different 
mechanisms in aSyn-mediated regulation of DAT function. This can probably 
explain why aSyn has either increased or decreased DAT function in different 
studies. Additionally, there have been different circumstances such as aSyn 
amount and conformation, mutated or wild-type aSyn, and different cell lines 
and models in vitro and in vivo. 
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Table 1. aSyn interactions in DAergic neurotransmission. 
Target Consequence Reference 
DA Increased aSyn oligomerization (Conway et al. 
2001) 
TH Decreased TH activity and DA 
synthesis 
(Perez et al. 2002) 
PP2A Downregulation of TH activity and 
DA synthesis 
(Hua et al. 2015, 
Peng et al. 2005) 
VAMP2 Membrane-bound aSyn promotes 
SNARE-complex assembly 
(Burré et al. 2010, 
Burré et al. 2014) 
VAMP2 aSyn oligomers inhibit SNARE-
mediated vesicle docking 
(Choi et al. 2013) 
SNAP-25, 
VAMP2 
aSyn aggregates reduce SNAP-25 
and VAMP2 impairing SNARE 
complex formation 
(Choi et al. 2018) 
SNARE 
proteoliposomes 
Promotion of vesicle docking in 
SNARE-complex 
(Lou et al. 2017) 
VMAT2 Reduced activity (Lotharius & 
Brundin 2002) 
PLD2 Inhibition reduces synaptic storage 
vesicles 
(Ahn et al. 2002, 
Jenco et al. 1998) 
DAT C-terminal DAT-aSyn complex stabilizes DAT 
on the plasma membrane leading to 
increased DA uptake 
(Lee et al. 2001, 
Wersinger & 
Sidhu 2003) 
PKC Inhibition alters DAT 
phosphorylation 
(Ostrerova et al. 
1999) 
ERK Inhibition alters DAT 
phosphorylation 
(Ostrerova et al. 
1999) 
COMT Downregulation decreases DA 
metabolism 
(Kurz et al. 2010) 
DOPAC Increased oxidation of DOPAC and 
accelerated formation of soluble 
aSyn oligomers 
(Zhou et al. 2009, 
Zhou et al. 2010) 
DOPAL Stabilization of aSyn oligomers, 
damage to cellular vesicles 
(Plotegher et al. 
2017) 
MAO-B Increased activity (Kang et al. 2018) 
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2.5 THE ROLE OF PROLYL OLIGOPEPTIDASE IN 
DOPAMINERGIC NEUROTRANSMISSION 
PREP is a highly conserved serine protease that cleaves small peptides shorter 
than 30 amino acids (Venäläinen et al. 2004, Camargo et al. 1979). PREP has 
been shown to cleave several peptide hormones in vitro, such as substance P, 
thyrotropin-releasing hormone, arginine-vasopressin, bradykinin, and 
neurotensin that are related to neurodegenerative diseases (Myöhänen et al. 
2009a), but the physiological role of PREP has remained unclear (Männistö et 
al. 2007, Männistö & García-Horsman 2017). PREP is widely distributed in 
different tissues in mammals but the highest activities have been measured in 
the brain (Fuse et al. 1990, Kato et al. 1980, Agirregoitia et al. 2007, Goossens 
et al. 1996). PREP has been found to localize in the GABAergic and cholinergic 
interneurons of the thalamus and cortex, and in the GABAergic and DAergic 
neurons in the nigrostriatal pathway (Myöhänen et al. 2008, Myöhänen et al. 
2009b). At the cellular level, PREP is mainly in the cytosol, and to some extent 
in the nucleus and bound to the membrane (Schulz et al. 2005, Myöhänen et 
al. 2009a). However, since the impact of PREP on neuropeptides in vivo has 
not been very conclusive (Jalkanen et al. 2012), the physiological role of PREP 
has remained a mystery. More recent studies have also suggested non-
hydrolytic functions for PREP and that protein-protein interactions might be 
more relevant than the hydrolytic function for the physiological role of PREP 
(Svarcbahs et al. 2019).  
PREP activity is altered in the brain tissue of PD, Alzheimer´s disease, 
Lewy body dementia, and Huntington´s disease patients (Mantle et al. 1996). 
Although earlier reports indicated elevated PREP activity, changes in activities 
differ a lot between the studies, and therefore, the true nature of PREP activity 
in neurodegenerative diseases is inconclusive. However, PREP colocalizes 
with aSyn in the PD brain, and with tau aggregates and beta-amyloid plaques 
in Alzheimer´s disease brains (Hannula et al. 2013), and it has been shown 
that PREP binds directly to aSyn and increases its aggregation in vitro and in 
mouse models of PD (Lambeir 2011, Savolainen et al. 2014, Savolainen et al. 
2015). PREP inhibitors can prevent aggregation and enhance the clearance of 
aggregates and oligomers in aSyn overexpressing cells and in aSyn transgenic 
mice (Myöhänen et al. 2012, Dokleja et al. 2014). 
PREP inhibitors KYP-2047 and JTP-4819 have been shown to decrease the 
extracellular concentration of DA in rat brain (Jalkanen et al. 2012) and 
increase tissue concentration of DA and immunoreactive DAT in the STR of 
A30P point-mutated transgenic mice (Savolainen et al. 2014). However, the 
mechanisms behind PREP regulation of the DA system are unclear. One 
possibility is that DAT function is regulated by ERK (Morón et al. 2003) and 
PREP inhibitors KYP-2047 and JTP-4819 are able to modulate 
phosphorylation of ERK (Moreno-Baylach et al. 2011, Tenorio-Laranga et al. 
2013), indicating that PREP could possibly regulate DAT function via ERK. 
Additionally, the interaction between PREP and aSyn could possibly modify 
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the interactions between aSyn and the nigrostriatal DAergic system, but PREP 
also has direct interactions with DAT and other players in DAergic 
neurotransmission which are investigated further in this thesis. 
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3 AIMS OF THE STUDY 
PREP has been shown to participate in regulation of the brain DAergic system 
in mice and rats. Although PREP inhibitors have been suggested for treating 
PD and possibly also for other neurodegenerative diseases, the mechanisms of 
PREP interaction with the nigrostriatal DAergic system are not known. The 
aim of this study was to characterize the role of PREP and aSyn in DAergic 
neurotransmission in the nigrostriatal tract in PD models. 
The effect of PREP and PREP inhibition and the interaction between PREP, 
aSyn and DAT were studied in vitro and in vivo. The specific aims of the 
studies were: 
 
I : To characterize the effect of expression, inhibition, absence and 
overexpression of PREP on DAT function in transfected HEK-293 
cells and on the nigrostriatal DAergic function in mice. 
II : To investigate the effect of PREP inhibitor treatment on behavior 
and the DAergic system in the AAV-aSyn mouse model of PD. 
III : To study if the toxicity of aSyn is dependent on the presence of 
PREP, and impact of this on the mouse DAergic system. 
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4 MATERIALS AND METHODS 
4.1 DRUGS AND REAGENTS 
Reagents used in experiments were purchased from Sigma-Aldrich if not 
otherwise specified. Ethanol was purchased from Altia (Helsinki, Finland). 
PREP inhibitor, 4-phenylbutanoyl-l-prolyl-2(S)-cyanopyrrolidine (KYP-
2047) was synthetized at the School of Pharmacy, University of Eastern 
Finland, as described previously by (Jarho et al. 2004).  
4.2 PLASMIDS 
pAAV1-EF1α-hPREP (#59967; Addgene, Cambridge, United States), pAAV1-
EF1α-S554A-hPREP (S554A-PREP; #59968; Addgene), and pAAV EF1a V5-
aSyn (WT) (#60057; Addgene), have been described previously (Savolainen et 
al. 2014). pAAV-EF1a control vector with 50 bp insert was created by 
annealing complementary oligonucleotides (10x annealing buffer: 100 nM 
Tris HCl, 500 mM NaCl, 10 mM EDTA). This insert was recombined into the 
KpnI-HF (R3142; NEB, Ipswich, United States) and EcoRV-HF (R3195; NEB) 
sites of pAAV-EF1a-PREP vector using an In-Fusion HD cloning kit (639645; 
Clontech, Mountain View, United States). Plasmid was transformed into Stbl3 
One-Shot competent cells (#C737303, ThermoFisher Scientific). An insert 
containing clone was verified by sequencing. pcDNA3.1-hDAT (#32810; 
Addgene) was a gift from Susan Amara. 
4.3 CELL EXPERIMENTS 
4.3.1 CELL LINES AND TRANSFECTION 
HEK-293 and stable PREPko cells generated in HEK-293 background were 
used in the study. PREPko cells were generated as described in publication IV. 
Wild-type HEK-293 cells were grown in Dulbecco´s modified Eagle´s medium 
(DMEM) containing an additional 10 % (v/v) fetal bovine serum (FBS; 
Invitrogen, Carlsbad, USA) and 1 % (v/v) penicillin-streptomycin (Lonza, 
Basel, Switzerland). PREPko cells were cultured in DMEM containing an 
additional 20 % (v/v) FBS (Invitrogen) and 1 % (v/v) penicillin-streptomycin 
(Lonza). Cell cultures were maintained at 37 °C in humidified air containing 5 
% CO2. 
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4.3.2 WESTERN BLOTTING 
To study phosphorylation of DAT and ERK by Western blotting, wild-type 
HEK-293 and PREPko cells were seeded with a density 6 x 105 cells per well 
the day before transfection on 6-well plates. Cells were transfected with DAT 
by using Lipofectamine 3000 transfection kit (Thermo Fisher, IL, USA) 
according to manufacturer´s protocol 2 days prior to cell lysis. DAT 
transfected cells were starved for 2 hours in serum free media prior to 
treatment with vehicle (0.01 % dimethyl sulfoxide (DMSO) (v/v)), 1 µM KYP-
2047, 1 µM PMA or 1 µM PMA + 1 µM KYP-2047 for 30 minutes. DAT 
transfected cells were treated with vehicle (0.01 % DMSO (v/v)), 1 µM KYP-
2047, 1 µM Gö-6983, or 1 µM Gö-6983 + 1 µM KYP-2047 without prior 
starvation. 
Cells were lysed on 150 µl ice-cold modified RIPA buffer (50 mM Tris HCl 
pH 7.4, 1 % NP-40, 0.25 % sodium deoxycholate, 150 mM NaCl) containing 
Halt Phosphatase Inhibitor (Product# 87786, Thermo Fisher Scientific) and 
Halt Protease Inhibitor cocktail (Product# 78430, Thermo Fisher Scientific). 
Cells were homogenized with an ultrasound sonicator (GM35-400, Rinco 
Ultrasonic, Switzerland). After centrifugation at 13 300 g and + 4 °C for 15 
min, the supernatants were collected. Protein concentration was measured by 
the bicinchoninic acid (BCA) method (Product #23225, Thermo Fisher 
Scientific). 30 μg of protein was loaded onto a 12 % Mini-PROTEAN TGX 
precast gel (Product # 4561044, Bio-Rad, CA, USA) for SDS-PAGE. Gel was 
transferred to PVDF membrane (Trans-blot Turbo, Product# 1620175, Bio-
Rad) by using Trans-blot Turbo Transfer System (Bio-Rad). The membranes 
were blocked by 5 % skim milk. The membranes were incubated with primary 
antibody overnight at + 4 °C and thereafter with secondary antibody for 2 
hours at room temperature. Antibodies were diluted in 5 % skim milk in 0,1 % 
Tween-20 in Tris-buffered saline (TTBS). The following primary antibodies 
and dilutions were used: DAT, rabbit anti-DAT (#PA1-4656, Thermo Fisher 
Scientific, dilution 1:1000); rabbit anti-phospho (T53)-DAT (pDAT) 
(#ab183486, AbCam, UK, dilution 1:500); ERK, rabbit anti-ERK1+ERK2 
(#ab17942, AbCam, dilution 1:1000), phospho ERK (pERK), mouse anti-
ERK1+ERK2 (#ab50011, Abcam, dilution 1:5000)  β-actin, rabbit anti-β-actin 
(#4967S, Signaling Technology, MA, USA, dilution 1:1000). Goat anti-rabbit 
HRP (#31460, Thermo Fisher Scientific) and goat anti-mouse HRP (#31430, 
Thermo Fisher Scientific) were used as secondary antibodies (dilution 
1:2000). The images were captured with ChemiDoc MP chemiluminescence 
scanner (Bio-Rad). Three independent Western blotting experiments were 
performed. Optical density (OD) values of the Western blotting images were 
analyzed using ImageJ software (NIH, MD, USA). The OD values were 
normalized to the loading control (β-actin) ODs. pDAT/DAT ratio and 
pERK/ERK ratio were calculated from values normalized to β-actin and wild-
type control was set as 100 %.  
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4.3.3 DOPAMINE UPTAKE ASSAY 
Cells were seeded (1.2 x 105 cells per well or 1.5 x 105 cells per well) the day 
before transfection in 24-well plates (Falcon 3047) coated with poly-l-lysine 
(Sigma-Aldrich). Cells were transfected 2 days prior to the experiment with 
DAT in combination with mock plasmid, PREP or S554A-PREP using 
Lipofectamine 3000 (Thermo Fisher) transfection protocol.  Media was 
removed and cells were washed once with 0.25 ml uptake buffer (5 mM Tris, 
7.5 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 1.2 mM MgSO4, 1 
mM ascorbic acid, 5 mM glucose; pH 7.1). Cells were preincubated in uptake 
buffer for 15 min (vehicle) or in uptake buffer containing 1 µM KYP-2047, 1 
µM PMA, 1 µM Gö-6983, 1 µM PMA + 1 µM KYP-2047 or 1 µM Gö-6983 + 1 
µM KYP-2047 for 30 min in + 37 °C prior to 5 min incubation with of 0.25 ml 
20 nM [3H] DA (PerkinElmer, Woodbridge, ON, Canada) containing 2 µM or 
10 µM unlabeled DA in + 37 °C. Cells treated with Gö-6983 were preincubated 
in media containing 1 µM Gö-6983 for 10 minutes before the other treatments. 
To observe phosphorylation of ERK, PMA treated cells and their control cells 
were starved in serum free media for 2 hours before the treatments. Wells were 
washed three times with ice-cold 0.32 M sucrose and lysed with 0.25 ml of 
0.25 M NaOH. Optiphase SuperMix (Perkin Elmer, Turku, Finland) scintillant 
was added to the wells, and radioactivity was quantified using a scintillation 
counter (Wallac 1450 MicroBeta TriLux Liquid Scintillation Counter & 
Luminometer, Turku, Finland) after placing cross-talk minimizing inserts 
(1450-109, Perkin Elmer) into each well. Counts per well were measured for 5 
min. 
4.3.4 PKC ACTIVITY ASSAY 
PKC activity was measured from wild-type HEK-293 cells with a PKC Kinase 
Activity Assay Kit (ab139437, Abcam) according to the manufacturer’s 
protocol. Briefly, cells were plated on poly-l-lysine (Sigma-Aldrich) coated 12-
well plates with a density of 2.5 x 105 per well. The following day the cells were 
treated with 0.1 % DMSO (vehicle), 10 µM KYP, 100 nM PMA (Sigma), 1 µM 
Gö-6983, 10 µM KYP + 100 nM PMA or 1 µM Gö-6983 + 100 nM PMA. When 
Gö-6983 was used in combination with PMA, it was added to the cells 10 min 
before PMA. The cells were treated for 30 min in + 37ᵒC and the treatments 
were performed in serum free media. After the treatment, the cells were 
washed once with PBS and lysed with lysis buffer containing 50 mM KH2PO4, 
1.5 mM MgCl2, 10 mM NaCl and 1 mM EDTA (pH 7.4) on ice. The cells were 
scraped, collected to Eppendorf tubes, and centrifuged (18 000 g, 15 min, + 4 
ᵒC). Supernatants were collected and diluted 1:20 to kinase assay dilution 
buffer provided in the kit. The diluted samples were pipetted to the 96-well 
plate included in the kit and the following steps were done according to the 
manufacturer’s instructions. The protein concentrations of the samples were 
measured with BCA and the PKC activities were normalized to the protein 
levels. 
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4.4 IN VIVO STUDIES 
4.4.1 ANIMALS 
PREP gene knock out mice (PREPko) (Deltagene Inc, CA, USA) and wild-type 
littermates were back crossed in C57Bl/6JRccHsd genetic background 
(Envigo, The Netherlands; 5–10 back crossings). Generation of PREPko mice 
used in these experiments has been described by (Di Daniel et al., 2009), and 
behavioral phenotyping was done by (Höfling et al., 2016). 
Mice (7-9 weeks old; Envigo, The Netherlands) were housed under 
standard laboratory conditions (12 h light/dark cycle; room temperature + 
23±2 °C; relative humidity: 50±15 %) in individually ventilated cages (Mouse 
IVC Green Line, Techniplast, Italy) with bedding (Aspen chips 5 x 5 x 1 mm, 
4HP, Tapvei, Estonia), nesting material (aspen strips, PM90L, Tapvei), and 
aspen brick (100 x 20 x 20 mm, Tapvei). Mice had access to chow food (Teklad 
2016, Envigo) and filtered and irradiated water ad libitum. After surgical 
procedures, animals were individually housed for the duration of the 
experiment. The experiments were carried out according to the European 
Communities Council Directive 86/609/EEC and were approved by the 
Finnish National Animal Experiment Board. Animal lisence number is 
ESAVI/441/04.10.07/2016. 
4.4.2 VIRAL VECTORS 
Adeno-associated viral vectors (AAV), AAV1-EF1α-hPREP (AAV-PREP), and 
AAV1-EF1α-eGFP (AAV-GFP), were obtained from the National Institute of 
Drug Abuse (Dr. Brandon Harvey, Intramural Research Program, Baltimore 
MD, USA). 
AAV vectors driven by chicken β-actin promoter (CBA) were acquired from 
the Michael J. Fox Foundation. AAV2-CBA-alpha-synuclein (AAV-aSyn; 
1.5x1013 vg/ml) and AAV2-CBA-eGFP (enhanced green fluorescent protein; 
AAV-GFP; 8.1x1012 vg/ml) were constructed, produced, and titered by Vector 
Core at the University of North Carolina (Chapel Hill, USA). pOTTC414 - 
pAAV1-EF1α-hPREP (AAV-PREP; Addgene plasmid #59967), pOTTC407 - 
AAV1-EF1α-GFP (AAV-GFP; Addgene plasmid #60058) and pOTTC293 - 
AAV-EF1a-V5-synuclein (WT; Addgene plasmid # 60057) was obtained from 
National Institute of Drug Abuse (Dr. Brandon Harvey, Intramural Research 
Program, Baltimore, MD, USA). 
4.4.3 SURGICAL PROCEDURES 
Mice were anesthetized with isoflurane (4 % induction, 1.5–2.0 % 
maintenance) and supranigral injection of AAV vector was given in a 
stereotaxic operation. To target the SN, viral vectors were given as a single 
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injection (volume 1 µL or 2 µL co-injection, rate 0.2 µL/min) into the left 
hemisphere, 3.1 mm anterior and 1.2 mm lateral to bregma, and 4.2 mm below 
the dura, stereotaxic coordinates according to (Paxinos G 1997). 
Characterization of the viral vectors showed protein expression 2 to 4 weeks 
after the microinjections in both SN and STR (data not shown). 
Animals for microdialysis experiments underwent the same set of virus 
vector microinjections (described above). Guide cannula (AT4.9.iC, 
AgnTho´s, Sweden) for microdialysis was inserted into the STR at 0.6 mm 
anterior and 1.8 mm lateral to bregma, and 2.7 mm below the dura 13-14 weeks 
after the injection of viral vector. The cannula was fastened to the skull with 
dental cement (Aqualox, Voco, Cuxhaven, Germany) and two stainless steel 
screws (1.2 × 3 mm, DIN84, Helsingin Ruuvihankinta, Finland). 
4.4.4 CYLINDER TEST 
The cylinder test (height, 15 cm; diameter, 12 cm) was used to measure motor 
asymmetry in spontaneous forelimb use after unilateral microinjections. 
Baseline paw preference scores were acquired prior to stereotaxic surgery and 
every 2 to 3 weeks after the surgery. Shortly, each mouse was filmed for 5 min. 
However, if the number of individual rearing episodes that resulted in the 
mouse touching the cylinder wall were <20, mouse was filmed for an 
additional 5 min. Data were analyzed by formula, where “both” paws was 
defined as touches where the animal landed both of the forepaws on the 
cylinder wall at the same time. Intact control mice should score ~50% in this 
test. No habituation of the animals to the testing cylinder was allowed before 
the experiment. One animal from aSyn injected and vehicle treated group was 
excluded from behavioral analyses for scoring too low in three out of five 
measurement times (<10 touches per record session). 
4.4.5 OPENFIELD ACTIVITY TEST 
The spontaneous locomotor activity of the AAV-aSyn and AAV-aSyn + AAV-
PREP injected mice was measured before the AAV-injections and every 2-3 
weeks after the injections for 13 weeks. The animals were placed in transparent 
cages (30 cm × 30 cm) with the activity monitor measuring infrared beam 
interruptions (MED Associates, GA, USA). Total distance (locomotor activity) 
and vertical activity were analyzed. Data was collected in 5 min intervals and 
activity was recorded for 2 hours. 
4.4.6 CONVENTIONAL MICRODIALYSIS 
Microdialysis was performed in the end of the PREP inhibitor treatment to 
AAV-GFP and AAV-aSyn injected mice as described earlier (Käenmäki et al. 
2010). A microdialysis probe (1-mm cuprophan membrane, o.d. 0.2 mm, 6 
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kDa cut-off; AT4.9.1. Cu,AgnTho’s, Sweden) was inserted into the guide 
cannula 2 hours prior to the experiment and the probe was perfused with a 
modified Ringer solution (147 mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 mM 
MgCl2, and 0.04 mM ascorbic acid) at a flow rate of 2.0 μL/min. Five baseline 
samples were collected (20 min/40 μL/sample) after the stabilization period. 
After the collection of baseline samples, the probe was perfused 2 × 20 min 
with 10 and 30 μM d-amphetamine sulphate with 2 × 20 min recovery time 
between the concentrations. 
The mice were euthanized right after the microdialysis experiment by 
cervical dislocation followed by decapitation. The brains were removed and 
rapidly frozen in isopentane on dry ice. The concentrations of DA, its 
metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA), and 5-hydroxyindoleacetic acid (5-HIAA) as well as gamma-
aminobutyric acid (GABA) in dialysates were measured using slightly 
modified versions of the HPLC methods that have been described earlier 
(Käenmäki et al. 2010, Vihavainen et al. 2008). 
4.4.7 NO-NET-FLUX MICRODIALYSIS 
No-net-flux microdialysis was performed with intact PREPko mice, their wild-
type littermates, and AAV-aSyn injected and AAV-aSyn + AAV-PREP 
coinjected PREPko and wild-type mice. Stabilization of the probe was 
performed as with the conventional microdialysis but the flow rate for probe 
perfusion was 0.6 μL/min. During the experiment, four concentrations of DA 
in Ringer solution (Cin; 0, 2, 10, and 20 nM) were perfused through the probe 
in a random order, and 3 × 30 min samples were collected at each 
concentration for HPLC analysis. Linear equation was constructed for each 
animal by plotting the net flux of DA through the probe (DAin − DAout) against 
DAin, where DAout is the dialysate DA concentration acquired during the 
perfusion and DAin is the DA concentration of the perfusion fluid. Based on 
this equation, the extracellular DA level (DAext) and the in vivo extraction 
fraction (Ed, the slope of the linear regression line) was calculated as described 
by (Parsons & Justice 1992). The DAext value stands for the perfusion fluid DA 
concentration at which there is no-net-flux of DA through the probe (DAin − 
DAout =0). Ed has been shown to describe combined DAT, NET, and uptake2 
functions (Chefer et al. 2006, Chefer et al. 2009, Smith & Justice 1994, Justice 
1993). 
4.4.8 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS 
Concentration of DA, its metabolites and 5-HIAA in the dialysate was 
measured by HPLC with electrochemical detection as earlier described 
(Käenmäki et al. 2010) with slight modifications and the concentration of 
GABA was measured by HPLC with fluorescence detection as earlier described 
(Vihavainen et al. 2008) with slight modifications. 
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HPLC system for determination of extracellular concentration of DA, its 
metabolites and 5-HIAA consisted of a solvent delivery pump (Jasco model 
PU-2080 Plus, Jasco International Co, Japan), pulse damper (SSI LP-21, 
Scientific Systems, State College, PA, USA), a refrigerated autosampler 
(Shimadzu SIL-20AC Autosampler, Shimadzu Co, Japan), an analytical 
column (Kinetex C-18 5 µm, 4.60 x 50 mm, Phemomenex Inc, USA) 
thermostated by a column heater (CROCO CIL, Cluzeau Info-Labo, France and 
LaChrom L-7350, Merck, Germany), an electrochemical detector (ESA 
Coulochem II detector, ESA Biosciences) and a model 5014B microdialysis cell 
(ESA Biosciences). The mobile phase consisted of 0.1 M NaH2PO4 buffer 
(Merck), 8 % (v/v) methanol (Merck), 0.2 M ethylenediaminetetraacetic acid, 
100 mg/l octanesulphonic acid, pH 4.0 and the flow rate was 1.0 ml/min. DA 
was reduced with an amperometric detector (potential -120 mV against an 
Ag/AgCl reference electrode) after being oxidized with a coulometric detector 
(+300 mV); DOPAC and HVA were oxidized with the coulometric detector. 
Injection volume was 20 µL for conventional microdialysis samples and 15 µL 
for no-net-flux microdialysis samples. The column temperature was kept at + 
45 °C. The chromatograms were processed by AZUR chromatography data 
system software (Cromatek, Essex, UK). 
The HPLC system for determination of the extracellular concentration of 
GABA consisted of a solvent delivery pump (Jasco model PU-1580 HPLC 
Pump, Jasco International Co, Japan) connected to an online degasser (Jasco 
3-Line Degasser, DG-980-50) and a ternary gradient unit (Jasco LG-1580-02), 
a refrigerated autosampler (Shimadzu NexeraX2 SIL-30AC Autosampler, 
Shimadzu Corp), an analytical column (Kinetex C-18 5 µm, 4.60 x 50 mm, 
Phemomenex Inc) protected by a 0.5-mm inlet filter and thermostated by a 
column heater (CROCO-CIL, Cluzeau Info-Labo, France), and a fluorescence 
detector (Jasco Intelligent Fluorescence Detector model FP-1520). The 
wavelengths of the fluorescence detector were set to 330 (excitation) and 450 
(emission). The mobile phase consisted of 0.1 M NaH2PO4 buffer (Merck), pH 
4.9 (adjusted with Na2HPO4), 20 % (v/v) acetonitrile (Merck), and the flow-
rate was 1.2 ml/min. Automated sample derivatization was carried out using 
the autosampler at + 8 °C. The autosampler was programmed to add 6 µL of 
the derivatizing reagent (3 µl of mercaptoethanol ad 1 ml of o-phtaldialdehyde) 
to 15 µl of a microdialysis sample, to mix two times, and to inject 20 µL onto 
the column after a reaction time of 1 min. The chromatograms were processed 
by AZUR chromatography data system software (Cromatek, Essex, UK). 
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4.5 TISSUE ANALYSES 
4.5.1 ANALYSIS OF BRAIN NEUROTRANSMITTERS AND 
METABOLITES 
Striatal tissue samples were punched below the corpus callosum +0.74 mm 
from the bregma to 2 mm depth by using sample corer (i.d. of 2 mm) with a 
plunger (Stoelting Co., USA) on a cryostat (Leica CM3050) and the samples 
from the SN were punched from a brain slice (thickness 1–1.5 mm) −2.8 mm 
from the bregma by using sample corer (i.d. of 1 mm) with a plunger (Stoelting 
Co.). Tissue processing and HPLC analysis of the concentrations of DA, its 
metabolites DOPAC and HVA, and 5-HIAA in the tissue were performed as 
described earlier by (Airavaara et al. 2006). 
4.5.2 HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY ANALYSIS 
Tissue concentration of DA, 5-HT and their metabolites were measured as 
earlier described (Airavaara et al. 2006) with slight modifications. The HPLC 
system consisted of a solvent delivery pump (ESA Model 582, ESA 
Biosciences), a refrigerated autosampler (Shimadzu SIL-20AC, Shimadzu 
Corp, Japan), a microdialysis cell (ESA Model 5014B, ESA Biosciences), an 
analytical column (Kinetex C-18 2.6 µm, 4.6 x 50 mm, Phenomenix Inc, USA) 
thermostated by a column heater (CROCO-CIL, Cluzeau Info Lab), a pulse 
damper (SSI LP-21, Scientific Systems, State College, PA, USA) and an 
electrochemical detector (ESA CoulArray 5600A, ESA Biosciences). The 
mobile phase consisted of 0.1 M NaH2PO4 buffer, 200 mg/l of octane sulfonic 
acid, methanol (10 %), and 0.2 M EDTA, and the flow-rate was 1.0 µl/min. 
Injection volume was 100 µl. The column temperature was kept at + 45 °C. 
Chromatograms were processed and concentrations of monoamines 
calculated using CoulArray for Windows software (ESA Biosciences, 
Chelmsford, USA). 
The tissue concentrations of GABA and glutamate were analyzed with 
HPLC equipped with a fluorescence detector. Injection volume was 10 µL and 
mobile phase consisted of 15 % (v/v) acetonitrile in glutamate measurement, 
otherwise the method was similar to GABA analysis of microdialysis samples 
as described above. 
4.5.3 WESTERN BLOTTING 
Western blotting was performed to measure expression level of TH, the rate 
limiting enzyme in DA synthesis, total DAT expression and phosphorylated 
DAT in the STR and SN of PREPko mice, their wild-type littermates, and AAV-
PREP or AAV-GFP injected mice. Frozen brain tissue was homogenized with 
an ultrasound sonicator (GM35-400, Rinco Ultrasonic, Switzerland) in five 
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volumes of ice-cold modified RIPA buffer (50 mM Tris HCl pH 7.4, 1 % NP-
40, 0.25 % sodium deoxycholate, 150 mM NaCl) containing Halt Phosphatase 
Inhibitor (Product# 87786, Thermo Fisher Scientific, IL, USA) and Halt 
Protease Inhibitor cocktail (Product# 78430, Thermo Fisher Scientific). After 
centrifuging at 16,000g and + 4°C for 15 min, the supernatants were collected. 
Protein concentration was measured by the BCA method (Thermo Fisher 
Scientific). For SDS-PAGE, 30 μg of protein was loaded onto a 4–20 % Mini-
PROTEAN TGX precast gel (Product # 4561094, Bio-Rad, CA, USA). Gel was 
transferred to nitrocellulose membrane (Trans-blot Turbo, Product# 1704158, 
Bio-Rad) by using Trans-blot Turbo Transfer System (BioRad). The 
membranes were blocked by 5 % skim milk. Western blotting for DAT, TH, 
and β-actin were done with SNAP i.d. 2.0 protein detection system (Merck 
Millipore, MA, USA), except phospho (T53)-DAT that was done by incubating 
the membrane with primary antibody overnight at + 4 °C and thereafter with 
secondary antibody for 2 h at room temperature. The following primary 
antibodies and dilutions were used: TH, rabbit anti-TH (#ab153, Merck 
Millipore, dilution 1:2000 in 0.5 % skim milk in 0.1 % TTBS); β-actin, rabbit 
anti-β-actin (#4967S, Signaling Technology, MA, USA, dilution 1:1000 in 0.5 
% skim milk in 0.1 % TTBS). DAT and pDAT antibodies and dilutions were 
similar to the cell samples in section 4.3.2 but the antibodies were diluted to 
0.5 % skim milk in 0.1 % TTBS. Goat anti-rabbit HRP was used as the 
secondary antibody for all the primary antibodies (#31460, Thermo Fisher 
Scientific, dilution 1:2000 in 0.5 % skim milk in 0.1 % TTBS). The images were 
captured with LI-COR C-digit chemiluminescence scanner (LI-COR, 
Germany). Three independent Western blotting experiments were performed. 
OD values of the Western blotting images were analyzed as with cellular 
Western blotting in the section 4.3.2. 
4.5.4 IMMUNOHISTOCHEMISTRY 
TH+ neurons in the SN and their TH+ positive fibers in the STR, and 
oligomeric aSyn were studied by immunohistochemistry staining in the AAV-
aSyn or AAV-GFP injected mice that received 4-week minipump treatment 
with KYP-2047 or vehicle. TH+ neurons, oligomeric aSyn and total aSyn were 
measured in the STR and SN of aSyn or aSyn+PREP injected wild-type and 
PREPko mice. 
Mice were deeply anesthetized with sodium pentobarbital (150 mg/kg) and 
transcardially perfused with PBS followed by 4 % paraformaldehyde (PFA) in 
PBS. Brains were postfixed for 24–72 h in 4 % PFA at + 4 °C and transferred 
to a solution of 10% sucrose in PBS (pH 7.4; 137 mM NaCl, 2.7 mM KCl, 10 
mM Na2HPO4, 1.8 mM KH2PO4) overnight at + 4 °C. On the next day, tissue 
was transferred to 30 % sucrose solution in PBS until brains sank. Brains were 
frozen on dry ice and were kept at -80°C until sectioning. Frozen brain sections 
were sectioned as 30 µm free-floating sections on a cryostat (Leica CM3050) 
and kept in a cryoprotectant solution (30 % ethylene glycol and 30 % glycerol 
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in 0.5 M phosphate buffer). Thereafter, brains were frozen in isopentane on 
dry ice and kept at -80°C until further analyses. 
TH immunohistochemistry staining was modified from the study by 
(Mijatovic et al. 2007). Shortly, the endogenous peroxidase activity was 
inactivated with 10% methanol and 3% hydrogen peroxide (H2O2) solution in 
PBS, pH 7.4, for 10 min, and nonspecific binding was blocked with 10% normal 
goat serum (catalog #S30, Millipore) in PBS containing 0.5% Triton X-100. 
The sections were incubated overnight at room temperature with rabbit anti-
TH primary antibody (1:2000; AB152, Millipore) in 1 % normal goat serum in 
PBS containing 0.5 % Triton X-100. On the following day, the sections were 
washed with PBS containing 0.5 % Triton X-100 and then incubated with goat 
anti-rabbit biotin-conjugated secondary antibodies (1:500; BA1000, Vector 
Laboratories) in 1% normal serum in PBS containing 0.5 % Triton X-100. The 
signal was enhanced with the avidin– biotin complex method (Standard 
Vectastain ABC kit, Vector Laboratories) followed by incubation with 0.05 % 
3,3´-diaminobenzidine (DAB) and 0.03 % H2O2 solution. Finally, the sections 
were transferred to glass slides, dehydrated in alcohol series, and mounted 
with Depex (BDH Chemicals, UK). 
Total aSyn immunohistochemistry staining was performed as described in 
(Myöhänen et al. 2012). Shortly, non-specific binding was blocked with 10% 
normal donkey serum (#S30, Millipore, Temecula, CA, USA). The sections 
were incubated overnight at room temperature with sheep anti-aSyn primary 
antibody (1:500; ab6162, AbCam, Cambridge, UK). The sections were then 
incubated with donkey anti-sheep HRP conjugated secondary antibody for 2 h 
(1:500; ab6900, AbCam). The antigen–antibody complexes were identified 
with DAB. 
Oligomer-specific aSyn immunohistochemistry staining was performed 
using the Basic Vector Mouse on Mouse (M.O.M.) Immunodetection Kit 
(BMK-2202, RRID:AB_2336833, Vector Laboratories) with an adapted 
protocol for mouse primary antibodies on mouse tissue (Brännström et al. 
2014). In aSyn oligomer staining, after blocking endogenous peroxidase 
activity (as above), the sections were incubated for 30 min in M.O.M. Mouse 
Ig Blocking Reagent to block nonspecific binding and 5 min in M.O.M. diluent, 
and transferred overnight in mouse anti-human aSyn oligomer-specific 
primary antibody (1:200 in M.O.M. diluent; AS132718, Agrisera). The sections 
were then incubated with goat anti-mouse HRP-conjugated secondary 
antibody (dilution, 1:300 in M.O.M. diluent, catalog #31430, Thermo Fisher 
Scientific) and visualized with DAB. 
4.5.5 MICROSCOPY AND STEREOLOGY 
ODs of TH stained ipsilateral and contralateral STR and SN were measured. 
Digital images were scanned at 40× magnification with a Pannoramic Flash II 
Scanner (3DHISTECH, Budapest, Hungary), and three coronal sections from 
each mouse were processed for further analyses with Pannoramic Viewer 
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(version 1.15.3., 3DHISTECH). Images were converted to grayscale and 
inverted, and line analysis tools for STR or freehand for SN in ImageJ (NIH) 
was used to measure the OD of immunoreactivity. To correct the effect of TH 
background staining, correction values were obtained from the corpus 
callosum of each section and subtracted from the OD values of the STR. The 
data are presented as percentages of the intact side. 
The number of TH+ cells in SN pars compacta (SNpc) was estimated using 
the optical fractionator method in combination with the dissector principle 
and unbiased counting rules (Gundersen et al. 1999). The SNpc was analyzed 
with a Stereo Investigator platform (MicroBrightField, Williston, VT, USA) 
attached to an Olympus BX51 microscope. From each animal, three sections 
from the central portion of the SNpc were selected for quantitative analysis. 
Each reference space was outlined at low magnification (4×), and cells were 
counted using a high-magnification (60× UPlanApo, 1.4 numerical aperture, 
oil immersion) objective. The grid size was 100×80 µm, and the counting 
frames were 60 × 60 µm. Injected and intact SNpc (internal control) was 
counted, no cell loss was observed in the noninjected side. The coefficient of 
error, calculated according to the procedure of (Schmitz & Hof 2005), was 
between 0.05 and 0.10. Results are expressed as the mean cell number per 
section; all stereological estimations were blinded. 
4.6 FAST-SCAN CYCLIC VOLTAMMETRY 
PREPko and wild-type littermate male mice (5-6 months of age) were 
decapitated and 300 µm thick coronal brain slices containing the cortex and 
the STR were cut on a vibratome (7000 smz-2, Campden Instruments, 
England) in ice-cold cutting saline containing 125 mM NaCl, 2.5 mM KCl, 26 
mM NaHCO3, 0.3 mM KH2PO4, 3.3 mM MgSO4, 0.8 mM NaH2PO4, and 10 
mM glucose. Slices were allowed to recover for 1–2 hours at + 32 °C in a 
holding chamber with oxygen-bubbled (95 % O2, 5 % CO2) recording saline 
containing 125 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 0.3 mM KH2PO4, 2.4 
mM CaCl2, 1.3 mM MgSO4, 0.8 mM NaH2PO4, and 10 mM glucose. In the 
recording chamber the slices were continuously perfused with + 35 °C oxygen-
bubbled recording saline. Fast-scan cyclic voltammetry recordings were 
performed with cylindrical 5 μm carbon fiber electrodes positioned at the 
dorsal STR ~50 μm below the slice surface. Striatal slices were electrically 
stimulated using a bipolar stainless steel electrode placed at a distance of ~100 
μm from the recording electrode. Square pulses of 0.2 sec duration were 
produced by DS3 stimulator (Digitimer Ltd, UK) that was triggered by a 
Master-8 pulse generator (A.M.P.I., Israel). Stimulus magnitude was selected 
by plotting a current–response curve to single pulse stimulations and selecting 
the minimum value that reliably produced the maximal response. Triangular 
voltage ramps from −450 mV holding potential to +900 mV over 9 ms (scan 
rate of 300 mV/ms) were applied to the carbon fiber electrode at 100 ms 
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intervals. Current was recorded with an Axopatch 200B amplifier (Molecular 
Devices LLC, CA, USA) filtered with 5 kHz low-pass Bessel filter and digitized 
at 40 kHz (ITC-18 board, InstruTech, NY, USA). Triangular wave generation 
and data acquisition were controlled and the recorded transients were 
characterized by a computer routine in IGOR Pro (WaveMetrics Inc,OR, USA) 
(Mosharov & Sulzer 2005, Mosharov 2008). Background-subtracted cyclic 
voltammograms, obtained with 1 µM DA solution (DA-HCl), were used to 
calibrate the electrodes. The DA terminals were stimulated with single 
electrical pulses at 2 min intervals or by a burst stimulation of 5 pulses at 20 
Hz, to study the release probability of the terminals. 
4.7 STATISTICAL ANALYSIS 
Statistical analysis was performed using either GraphPad Prism (version 6.02, 
GraphPad Software, Inc., CA, USA) or SPSS Statistics (Version 22.0.0.1 IBM 
Corporation, NY, USA) software. One-way ANOVA, two-way ANOVA and 
repeated measures ANOVA with Tukey´s or Bonferroni´s post-hoc test were 
used as statistical tests. Data are presented as mean ± standard error of the 
mean (SEM). The results were considered to be statistically significant at p < 
0.05. 
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5 RESULTS 
PREP has been shown to participate in regulation of the nigrostriatal DAergic 
system in aSyn transgenic mice (Savolainen et al. 2014) and PREP inhibitors 
can modulate striatal DA level in the rat brain (Jalkanen et al. 2012). Based on 
these findings we decided to further study the interaction between DA and 
PREP. We studied the mechanisms of PREP as a regulator of DAT in wild-type 
HEK-293 cells and stable PREPko cells. Inhibition, absence and 
overexpression of PREP and restoring PREP function to PREPko cells was 
studied by Western blotting, a DA uptake assay, and a PKC activity assay 
(Study I). 
PREPko mice were used to study the role of PREP in the nigrostriatal 
DAergic pathway in vivo. Absence, overexpression and inhibition of PREP was 
studied in PREPko mice and wild-type littermates by no-net-flux 
microdialysis, fast-scan cyclic voltammetry, HPLC tissue analysis, and 
Western blotting (Study II). 
Additionally, as PREP enhances the aggregation of aSyn – the key player in 
PD cellular toxicity – and PREP inhibition can decrease this process, we 
wanted to study the impact of PREP inhibitor treatment on DAergic signaling 
in the AAV-aSyn mouse model of PD. The effect of the treatment on 
nigrostriatal DAergic function was studied by conventional microdialysis and 
tissue HPLC analysis. In addition, behavioral tests and 
immunohistochemistry were used to evaluate aSyn toxicity and 
neuroprotective effects of a PREP inhibitor (Study III). Since the PREP 
inhibitor had a beneficial effect in the aSyn mouse model in Study III, we 
studied if the toxicity of aSyn and its negative impact on nigrostriatal DAergic 
neurotransmission is dependent on PREP expression in publication IV. 
5.1 PREP AND Α-SYNUCLEIN AS REGULATORS OF 
DOPAMINE TRANSPORTER FUNCTION IN HEK-293 
CELLS 
PREP inhibitor KYP-2047 has been shown to decrease tissue concentration of 
DA in the STR of A30P point-mutated transgenic mice and immunoreactive 
DAT in the STR of aSyn transgenic and wild-type mice (Savolainen et al. 2014). 
Phosphorylation of DAT regulates DAT function as phosphorylated DAT is 
internalized leading to decreased plasma membrane localization and 
decreased re-uptake of DA (Vaughan et al. 1997, Copeland et al. 1996). ERK 
participates in regulation of DAT phosphorylation (Morón et al. 2003) and 
PREP is involved in ERK phosphorylation and activation (Moreno-Baylach et 
al. 2011, Tenorio-Laranga et al. 2013). PKC regulates DAT phosphorylation by 
activating ERK and also by binding directly to DAT (Vaughan et al. 1997, Huff 
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et al. 1997).  Based on these findings we hypothesized that PREP could 
regulate DAT function via ERK and PKC. We investigated the effect of PREP 
overexpression, inactive S554A-PREP, lack of PREP and restoring PREP on 
DAT phosphorylation and function in transfected wild-type HEK-293 cells 
and stable PREPko HEK-293 cells by Western blotting and by the 3H-DA 
uptake assay. ERK expression and phosphorylation were also measured to 
study if changes in DAT function are ERK-mediated. Additionally, we studied 
if aSyn is able to modify the effect of PREP. The effect of PREP inhibition on 
PKC activity was measured to investigate if PREP-mediated modulation of 
DAT function is dependent on PKC. 
5.1.1 THE EFFECT OF PREP AND α-SYNUCLEIN ON DOPAMINE 
TRANSPORTER PHOSPHORYLATION AND FUNCTION, AND 
ERK PHOSPHORYLATION 
Active PREP or inactive S554A-PREP overexpression did not have a 
statistically significant effect on pDAT/DAT ratio (Figure 5A, F5,23 = 1.030, p 
= 0.430, one-way ANOVA) or pERK/ERK ratio (Figure 5C, F5,23 = 0.395, p = 
0.846, one-way ANOVA) but there was a trend for elevated pDAT/DAT ratio 
in PREPko cells compared to wild-type cells (Figure 5A, F1,23 = 3.948, p = 
0.062, two-way ANOVA). Overexpression of aSyn did not change the 
pDAT/DAT ratio (Figure 5B, F5,23 = 6.865, p = 0.991, one-way ANOVA, 
Tukey´s post-hoc test) in wild-type HEK-293 cells or the pERK/ERK ratio 
(Figure 5D, F5,23 = 0.851, p = 0.532, one-way ANOVA) in wild-type and 
PREPko HEK-293 cells but aSyn (Figure 5B, (F5,23 = 6.865, p = 0.006, one-
way ANOVA, Tukey´s post-hoc test) and combination of aSyn and PREP 
(Figure 5B, F5,23 = 6.865, p = 0.0007, one-way ANOVA, Tukey´s post-hoc test) 
lowered the pDAT/DAT ratio in PREPko cells. 
Overexpression of PREP or inactive S554A-PREP did not have an effect on 
DA uptake in wild-type or PREPko HEK-293 cells (Figure 6A). Co-expression 
of aSyn and DAT (Figure 6B, F5,52 = 3.957, p = 0.037, one-way ANOVA, 
Tukey´s post-hoc test), and co-expression of PREP, aSyn and DAT (Figure 6, 
F5,52 = 3.957, p = 0.002, one-way ANOVA, Tukey´s post-hoc test) decreased 
DA uptake in PREPko cells compared to wild-type HEK-293 cells that were 
transfected with DAT and mock. There was also a similar trend in mock and 
DAT transfected PREPko cells (Figure 6B, F5,52 = 3.957, p = 0.086, one-way 
ANOVA, Tukey´s post-hoc test). Two-way ANOVA revealed a statistically 
significant difference between wild-type and PREPko cells (Figure 6B, cell line 
effect; F1,52 = 12.442, p = 0.0009, two-way ANOVA) and between mock and 
DAT and PREP, aSyn and DAT transfected cells (Figure 6B, treatment effect; 
F2,52 = 3.442, p = 0.037, two-way ANOVA, Tukey´s post-hoc test). 
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Figure 5 PREP and aSyn regulate phosphorylation of DAT. DAT, pDAT, ERK, and pERK were 
measured by Western blotting in wild-type HEK-293 and stable PREPko HEK-293 cells 
transfected with DAT and mock, DAT and PREP or DAT and inactive PREP (S554A-PREP) 
(A, C and E), or DAT and mock, DAT and aSyn or DAT, aSyn, and PREP (B, D and F). 
Representative Western blotting figures for A and C (E), and B and D (F). Bars represent mean 
± SEM, n = 4, **p < 0.01, ***p < 0.001, one-way ANOVA with Tukey´s post-hoc comparison. 
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Figure 6 The effect of PREP on DA uptake in wild-type and stable PREPko cells. Uptake of 
3H-DA was measured in wild-type and stable PREPko cells transfected with DAT and active 
or inactive PREP (A), or DAT and aSyn with or without PREP (B) and in DAT transfected wild-
type cells that were treated 30 minutes with PREP inhibitor and PKC activator or inhibitor (C, 
D). Cells were starved in serum free media 2 hours before treatment and then treated with 1 
µM KYP, 1 µM PMA or 1 µM KYP + 1 µM PMA for 30 minutes (C). Cells treated with 1 µM 
KYP, 1 µM Gö-9683 1 µM KYP + 1 µM Gö-6983 for 30 minutes were not starved (D). Data are 
from 3 independent experiments for cells with 3 replicates. Bars represent mean ± SEM, n = 
4, *p < 0.05, **p < 0.01, one-way ANOVA or two-way ANOVA with Tukey´s post-hoc test. 
 
5.1.2 PREP INHIBITOR KYP-2047 POTENTIATES THE EFFECT OF PKC 
ACTIVATOR PMA 
Cells were starved before a PKC activator, PMA, was added to reduce high 
basal PKC activity which could cover changes in PKC activity. Western blotting 
and PKC activity assays were performed to measure the impact of PMA and 
PREP inhibitor (KYP-2047). KYP-2047 treatment did not have an effect on the 
pDAT/DAT ratio (Figure 7A, F3,15 = 6.030, p = 1.000, one-way ANOVA, 
Tukey´s post-hoc test) or the pERK/ERK ratio (Figure 7C, F3,15 = 10.124, p = 
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1.000, one-way ANOVA, Tukey´s post-hoc test) in starved cells. pDAT/DAT 
ratio (Figure 7B, F3,15 = 0.886, p = 0.736, one-way ANOVA, Tukey´s post-hoc 
test) or pERK/ERK ratio (Figure 7D, F3,15 = 4.832, p = 0.890, one-way 
ANOVA, Tukey´s post-hoc test) were not altered without starvation either. 
PMA, used as positive control, elevated the pERK/ERK ratio (Figure 7C, F3,15 
= 10.124, p = 0.018, one-way ANOVA, Tukey´s post-hoc test) but the decrease 
in the pDAT/DAT ratio was not statistically significant (Figure 7A, F3,15 = 
6.030, p = 0.103, one-way ANOVA, Tukey´s post-hoc test). Combination of 
KYP-2047 and PMA elevated the pDAT/DAT ratio (Figure 7A, F3,15 = 6.030, p 
= 0.023, one-way ANOVA, Tukey´s post-hoc test) and the pERK/ERK ratio 
(Figure 7C, F3,15 = 10.124, p = 0.006 one-way ANOVA, Tukey´s post-hoc test) 
statistically significantly  but the combination did not have a statistically 
significant difference to PMA alone. 
PKC inhibitor Gö-6983 did not have an effect on phosphorylation of DAT 
in non-starved cells (Figure 7B) but combination of Gö6983 and KYP-2047 
decreased phosphorylation of ERK (Figure 7D, F3,15 = 4.832, p = 0.029 one-
way ANOVA, Tukey´s post-hoc test). There was also a similar trend in the 
pERK/ERK ratio with Gö-6983 alone (Figure 7D, F3,15 = 4.832, p = 0.087, one-
way ANOVA, Tukey´s post-hoc test). 
The effect of PREP inhibition on PKC activity was studied by PKC activity 
assay since PKC-mediated phosphorylation of DAT is one of the main 
regulators of DAT function and internalization, and PKC phosphorylates ERK. 
PMA was used as a positive control and Gö-6983 as a negative control. As 
predicted, there was a trend for increased PKC activity induced by PMA 
(Figure 7F, F5, 15 = 10.63, p = 0.074, one-way ANOVA, Tukey´s post-hoc test) 
but the negative control Gö-6983 did not have much effect on PKC activity. 
However, Gö-6983 was able to abolish the effect of PMA, verifying that PMA-
induced signal was indeed PKC activity. KYP-2047 alone did not have an effect 
on PKC activity but it potentiated the effect of PMA since combination of KYP-
2047 and PMA induced a statistically significant increase in PKC activity 
(Figure 7F, F5, 15 =10.63, p = 0.018, one-way ANOVA, Tukey´s post-hoc test). 
Similar potentiation of the effect of PMA was also observed in 3H-DA 
uptake assay. KYP-2047 alone did not have a statistically significant effect on 
uptake in starved wild-type HEK-293 cells (Figure 6C, F3,32 = 3.052, p = 0.643, 
one-way ANOVA, Tukey´s post-hoc test) or without starvation (Figure 6D, 
F3,31 = 0.517, p = 0.455, one-way ANOVA, Tukey´s post-hoc test). Combination 
of PMA and KYP-2047 reduced DA uptake (Figure 6C, F3,32 = 3.052, p = 0.026, 
one-way ANOVA) while PMA alone did not have a statistically significant 
effect (Figure 6C, F3,32 = 3.052, p = 0.413, one-way ANOVA). PKC inhibitor 
Gö-6983 did not have a statistically significant effect on DA uptake alone 
(Figure 6D, F3,31 = 0.517, p = 0.180, one-way ANOVA, Tukey´s post-hoc test) 
or combined with KYP-2047 (Figure 6D, F3,31 = 0.517, p = 0.183, one-way 
ANOVA, Tukey´s post-hoc test). 
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Figure 7 Wild-type HEK-293 cells were starved for 2 hours in serum free media and then 
treated with 1 µM KYP-2047, 1 µM PMA or 1 µM KYP-2047 +  1 µM PMA for 30 minutes before 
cell lysis (A, C). Wild-type HEK-293 cells were treated with 1 µM KYP-2047, 1 µM Gö-6983 or 
1 µM KYP-2047 + 1 µM Gö-6983 for 30 minutes without starvation (B, D). Representative 
Western blots for A-D (E). pDAT/DAT ratio and pERK/ERK ratio were measured from Western 
blots that were normalized to b-actin. pDAT/DAT and pERK/ERK ratio of control cells were set 
as 100 %. n = 4. Bars represent mean ± SEM, *p < 0.05, **p < 0.01, one-way ANOVA with 
Tukey´s post-hoc comparison. 
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5.2 PREP REGULATES DOPAMINE TRANSPORTER 
PHOSPHORYLATION AND FUNCTION IN THE 
NIGROSTRIATAL PATHWAY IN MICE 
The effect of absence or overexpression of PREP on the DAergic function in 
the nigrostriatal pathway of mouse was studied in PREPko mice and their 
wild-type littermates, and in wild-type mice that received supranigral 
microinjection of AAV-GFP or AAV-PREP. Extracellular DA level was 
measured by striatal no-net-flux microdialysis, and DA release and uptake 
were studied in acute striatal slices by fast-scan cyclic voltammetry in PREPko 
mice and their wild-type littermates. DAT expression and phosphorylation 
and TH expression in the STR and SN were studied by WB in PREPko animals, 
wild-type littermates, and AAV-injected mice.  
Extracellular DA concentration was elevated in the STR of PREPko mice 
compared to wild-type littermates in the no-net-flux microdialysis study 
(Figure 8A, p = 0.03, Student´s t-test). Fast-scan cyclic voltammetry revealed 
that DA release was similar in the STR of PREPko mice and wild-type 
littermates (Figure 8C, p = 0.356, Student´s t-test), but the half widths (Figure 
8D, p = 0.002, Student´s t-test) and tau values (Figure 8E, p = 0.028, 
Student´s t-test) of the DA release peak were increased in PREPko animals, 
and there was a similar trend in the fall time (Figure 8F, Student´s t-test) 
indicating delayed DA re-uptake and impaired DAT function in the PREPko 
STR. 
Lack of PREP did not have an effect on total DAT expression in the STR 
(Figure 9A) or SN (Figure 9B), but phosphorylated DAT was elevated in the 
STR of PREPko mice (Figure 9C, p = 0.034, Student´s t-test). Changed 
phosphorylation of DAT was not observed in the SN (Figure 9D). TH 
expression was similar in the STR of PREPko mice and wild-type littermates 
(Figure 9E), but elevated TH expression was observed in the SN of PREPko 
mice (Figure 9F, p = 0.004, Student´s t-test). 
Overexpression of PREP in the nigrostriatal tract elevated DAT expression 
in the STR (Figure 10A, p = 0.027, Student´s t-test) and in the SN (Figure 10B, 
p = 0.033, Student´s t-test) measured by Western blotting. pDAT was 
decreased in the STR of PREPko mice (Figure 10C, p = 0.028, Student´s t-
test), but it was not altered in the SN (Figure 10D). AAV-PREP injection did 
not have an effect on the striatal (Figure 10E) or nigral TH expression level 
(Figure 10F). 
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Figure 8 PREPko mice (KO) had higher extracellular DA concentration in the STR than wild-
type mice in the no-net-flux microdialysis study (A). Fast-scan cyclic voltammetry revealed 
delayed re-uptake of DA in PREPko mice compared to wild-type littermates (B). The height of 
DA release peak was similar in wild-type and PREPko mice (C) but half width (D) and Tau 
values (E) were elevated in PREPko mice and there was a similar trend in the fall time (F). A : 
n = 5-6, B-F n = 13-14. Bars represent mean ± SEM, *p < 0.05, **p < 0.01, Student´s t-test.  
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Figure 9 DAT (A-B), pDAT (C-D), and TH (E-F) were measured by Western blotting in the STR 
and SN tissue of PREPko and wild-type mice. DAT was unchanged in the STR (A) and in the 
SN (B). pDAT was elevated in the STR (C) but not in the SN (D) in PREPko mice. TH was 
elevated in the SN (F) but not in the STR (E) of PREPko mice. n = 3-4. Bars represent mean 
± SEM, *p < 0.05, **p < 0.01, Student´s t-test. 
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Figure 10 DAT (A-B), pDAT (C-D), and TH (E-F) were measured by Western blotting in the STR 
and SN tissue 5 weeks after a supranigral injection of AAV-eGFP or AAV-hPREP. 
Overexpression of PREP increased DAT in the STR (A) and in the SN (B). pDAT was 
increased in the STR (C) but not in the SN (D). TH was not changed (E-F). n = 3-4. Bars 
represent mean ± SEM, *p < 0.05, Student´s t-test. 
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5.3 PREP INHIBITOR RESTORES BEHAVIOR AND 
DOPAMINERGIC FUNCTION IN Α-SYNUCLEIN 
OVEREXPRESSION MODEL OF PARKINSON´S 
DISEASE 
The effect of PREP inhibitor treatment on behavior and the nigrostriatal 
DAergic system was studied in the AAV-aSyn mouse model of PD. AAV-aSyn 
or AAV-GFP were injected above the SN to cause progressive aSyn aggregation 
and DAergic neurodegeneration to SN and STR to model PD. 4-week KYP-
2047 (10 mg/kg per day) or vehicle minipump treatment was started 4 weeks 
post-injection and the behavior of mice was evaluated every 2 weeks by 
cylinder test. The effect of aSyn overexpression and KYP-2047 treatment on 
the nigrostriatal DAergic system was evaluated by TH immunohistochemistry 
staining to observe cell loss in the STR and SN, by striatal microdialysis to 
measure extracellular DA and its metabolites, and by tissue HPLC analysis to 
measure striatal and nigral tissue concentrations of DA and its metabolites. 
Unilateral overexpression of aSyn reduced use of the forepaw contralateral 
to the injected hemisphere at 2 weeks and 4 weeks post-injection compared to 
AAV-GFP injected control mice (Figure 11, F1,31 = 16.873. p = 0.0003, repeated 
measures two-way ANOVA). KYP-2047 minipump treatment restored the use 
of contralateral forepaw but impaired behavior retained in the aSyn-vehicle 
group (main effect for the treatment, F1,29 = 5.575, p = 0.025, combined 
treatment by virus  F ratio, F1,29 = 6.802, p = 0.014, repeated-measures two-
way ANOVA; difference between GFP groups and aSyn-vehicle group, p < 
0.05, Tukey´s post-hoc test). 
aSyn overexpression did not have a statistically significant effect on the cell 
count of TH+ cells in the SN (Figure 12A, B, F3, 28 = 2.784, p = 0.059, one-way 
ANOVA), but TH+ OD was reduced in the STR (Figure 12A, C, F3, 29 = 4.229, p 
= 0.014, aSyn-vehicle vs GFP-vehicle, one-way ANOVA) and in the SN (Figure 
12A, D, F3,30 = 7.366, p = 0.0008, one-way ANOVA; p < 0.01, aSyn-vehicle vs 
GFP-vehicle and GFP-KYP, Tukey´s post-hoc test) in the AAV-aSyn injected 
vehicle treated mice compared to the AAV-GFP injected control mice. 
Intriguingly, similar reduction was not observed in the AAV-aSyn injected 
mice that received KYP-2047 treatment (Figure 12A, C, D). Nevertheless, 
immunohistochemistry showed that KYP-2047 treatment significantly 
reduced oligomeric aSyn particles in the SN (Figure 12E, p < 0.0001, 
Student´s t-test). 
Overexpression of aSyn decreased striatal extracellular DA metabolites 
DOPAC and HVA statistically significantly (Figure 13B, F1,35 = 4.164, p = 
0.049, two-way ANOVA) and there was a similar trend in DA (Figure 13A, F1,35 
= 3.758, p = 0.061, two-way ANOVA) in the microdialysis study, but KYP-2047 
treatment did not have a significant effect on DA (Figure 13A, aSyn-vehicle vs. 
aSyn-KYP, p = 0.129, Student´s t-test) or its metabolites (Figure 13B, aSyn-
vehicle vs. aSyn-KYP, p = 0.435, Student´s t-test) in AAV-aSyn injected mice.  
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Tissue concentration of DA was reduced by aSyn overexpression in the STR 
(Figure 13C, F1,41 = 6.502, p = 0.015, two-way ANOVA) and there was a similar 
trend for metabolites of DA (Figure 13D, F1,41 = 3.611, p = 0.064, two-way 
ANOVA). DA concentration was not changed in SN (Figure 13E), but the 
metabolites of DA were decreased (Figure 13F, F1,41 = 6.502, p = 0.015, two-
way ANOVA). 
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Figure 11 KYP-2047 treatment restores motor behavior in cylinder test in aSyn overexpressing 
mice. AAV-eGFP or AAV-aSyn were injected above SN and 4-week minipump treatment with 
vehicle (VEH) or KYP-2047 (KYP) was started 4 weeks post-injection. Motor behavior was 
evaluated by cylinder test every two weeks. aSyn overexpression caused increased use of 
ipsilateral paw two weeks after the AAV-injections and KYP-treatment restored use of 
ipsilateral paw on the baseline level two weeks after the minipump implantation. Until 6 weeks: 
n = 7-9, at 8 weeks: n = 4-7. Bars represent mean ± SEM. *p < 0.05, aSyn-vehicle vs. GFP-
vehicle; ^^p < 0.01, aSyn-KYP vs. GFP-KYP; ##p < 0.01, aSyn-vehicle vs. aSyn-KYP; §§p < 
0.01, aSyn-vehicle vs. aSyn-KYP, GFP-vehicle, and GFP-KYP, two-way ANOVA with Tukey’s 
post hoc comparison. 
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Figure 12 aSyn overexpression decreased TH+ cells and TH immunoreactivity in the STR and 
in the SN. Mice received supranigral injection of AAV-GFP and AAV-aSyn and 4 weeks post-
injection intraventricular 4-week treatment with vehicle (VEH) or KYP-2047. Representative 
images of TH+ immunoreactivity in the STR and in the SN (A). aSyn did not have a statistically 
significant effect on the TH+ cell stereology (B) but TH+ OD in the STR (C) and SN (D) was 
decreased in the vehicle-treated AAV-aSyn injected mice compared to AAV-GFP injected 
control groups. Similar decrease was not observed in KYP-2047 treated AAV-aSyn injected 
mice (C, D). 4-week KYP-2047 treatment reduced immunoreactive aSyn oligomer particles in 
the SN 8 weeks after AAV-aSyn injection compared to AAV-GFP-injected animals (E). n = 7-
9. Bars represent mean ± SEM, *p < 0.05, **p < 0.01, ****p < 0.0001, one-way ANOVA with 
Tukey´s post-hoc comparison (B-D), unpaired Student´s t-test (E). Scale bars: 100 µm; inserts 
15 µm. 
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Figure 13 Overexpression of aSyn decreased extracellular and tissue concentration of DA in 
the STR and its metabolites DOPAC and HVA in the STR and SN in wild-type mice. Mice 
received supranigral injection of AAV-GFP or AAV-aSyn, and vehicle (VEH) or KYP-2047 
minipump treatment was started 4 weeks post-injection. Extracellular level of DA (A) and its 
metabolites DOPAC and HVA (B) were measured by striatal microdialysis, and striatal (C, D) 
and nigral (E, F) tissue concentrations by HPLC analysis after 4-week treatment. 
Overexpression of aSyn lowered DOPAC and HVA statistically significantly (B) and there was 
a similar trend for DA (A). aSyn decreased DA in the striatal tissue (C) and metabolites in the 
nigral tissue (F) and there was a similar trend for metabolites in the STR (D) but nigral DA was 
not affected (E). KYP-2047 treatment did not have a significant effect on DA or its metabolites. 
n = 8-11. Bars represent mean ± SEM. *p < 0.05; ***p < 0.001; #p = 0.06, two-way ANOVA. 
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5.4 REMOVAL OF PREP REDUCES α-SYNUCLEIN 
TOXICITY IN THE MOUSE BRAIN 
To characterize the role of PREP on aSyn aggregation and toxicity, and the 
impact of this on the DAergic system, we restored PREP in the presence and 
absence of aSyn in the PREPko mouse nigrostriatal pathway, and similarly 
used overexpression in the wild-type mouse. The nigrostriatal DAergic system 
was studied by striatal no-net-flux microdialysis and tissue HPLC analysis 14-
15 weeks after supranigral injection of AAV-aSyn or co-injection of AAV-aSyn 
and AAV-PREP to PREPko mice or wild-type littermates. The behavioral 
effects were investigated by locomotor activity test and cylinder test before the 
viral vector injections, and starting 2 weeks after the injections animals were 
tested every 3 weeks until 13 weeks. Distribution of aSyn, and loss of TH+ 
fibers in the STR and TH+ cells in the SN were evaluated by 
immunohistochemistry staining of total aSyn, oligomeric aSyn, and TH. 
Locomotor activity in PREPko mice was restored to the levels of wild-type 
animals after the coinjection of PREP and aSyn (Figure 14A).There was a 
statistically significant interaction between the aSyn and aSyn+PREP injected 
animals and time on traveled distance in the PREPko mice (Figure 14A, F5, 75 
= 4.174, p = 0.002, two-way ANOVA). The traveled distance was decreased in 
the PREPko mice that received coinjection of aSyn+PREP at the 5-week 
timepoint (Figure 14A, F1, 15 = 5.612, p = 0.032, univariate analysis) and the 
difference extended until the last timepoint at 13 weeks (Figure 14A, F1,15 = 
7.642, p = 0.014). Similar changes were not observed in the wild-type mice 
(Figure 14A, F5,70 = 1.002, p = 0.395, two-way ANOVA). 
The interaction between the viral vector and ipsilateral paw use was not 
significant in PREPko mice (Figure 14B, F5,145 = 0.639, p = 0.622, two-way 
ANOVA) or in wild-type littermates (Figure 14B. F5,150 = 1.696, p = 0.139, two-
way ANOVA). However, the main effect over time showed a statistically 
significant difference in ipsilateral paw use in wild-type mice (Figure 14C, F5,150 
= 5.453, p = 0.001, two-way ANOVA with Bonferroni´s adjustment) indicating 
aSyn-induced toxicity. Paw preference was  changed statistically significantly 
in wild-type mice 2 weeks after the injections compared to baseline level (p < 
0.0005) and the difference remained until the end of the experiment 13 weeks 
post-injections (Figure 14B, p = 0.007). 
Immunohistochemistry staining showed that oligomeric aSyn was not 
changed statistically significantly in any of the groups (Figure 15B) contrary to 
observations of PREP inhibitor treatment in Study III. However, TH+ cells in 
the SN were decreased more in aSyn+PREP co-injected wild-type and PREPko 
mice than in aSyn injected wild-type and PREPko mice (Figure 15A, F1,23 = 
7.965, p = 0.0097, two-way ANOVA). Nevertheless, TH OD analysis did not 
show loss of TH+ fibers in the STR or in the SNpc (Figure 16D, E, G) but the 
SNpr two-way ANOVA revealed a statistically significant effect for viral vector 
injections (Figure 16F, G; F1,25 = 4.838, p = 0.037, two-way ANOVA), and for 
phenotype (Figure 16C, G; F1,25 = 4.410, p = 0.046, two-way ANOVA).   
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Figure 14 PREPko mice were resistant to the aSyn-induced changes in the behavioral tests. 
Total traveled distance was significantly reduced in PREPko mice that received aSyn+PREP 
co-injection compared to PREPko mice that received only aSyn starting 5 weeks after the 
injections and the difference extended until the end of the experiments. n = 7-10 (A). Use of 
ipsilateral paw was increased only in the wild-type (wt) mice that received aSyn or aSyn+PREP 
injection but this difference was not seen in the PREPko mice. n = 15-17 (B). Bars represent 
mean ± SEM. *p < 0.05, ####p < 0.0005, wild-type vs. PREPko; ^p < 0.05, ^^p < 0.01, ^^^p < 
0.001, ^^^^p < 0.0005, wild-type mice baseline (BL) vs. post-injection measurements, two-way 
ANOVA with univariate analyses, Student´s t-test for BL locomotor activity. 
The effect of aSyn and PREP overexpression on extracellular DA was 
studied by no-net-flux microdialysis and on tissue concentration of striatal 
DA, its metabolites and GABA by HPLC tissue analysis. The level of 
extracellular DA was similar in all groups in the no-net-flux microdialysis 
experiment (Figure 15C). Striatal DA was significantly decreased compared to 
the intact side of the brain in all other groups (Figure 15D, F 7,56 = 9.403, wt-
aSyn p = 0.002, wt-aSyn + PREP p = 0.008, PREPko-aSyn p = 0.007, one-way 
ANOVA with Tukey’s post hoc comparison) except in PREPko mice that 
received aSyn + PREP injection (Figure 15D, F 7,56 = 9.403, p = 0.218), but 
DOPAC was increased significantly only in this group (Figure 15E, F 7,56 = 
3.296, p = 0.009). AAV-injections did not have an effect on striatal 
extracellular HVA (Figure 15F) or GABA (Figure 15G). 
 
The main findings of the role of PREP in the nigrostriatal DAergic function are 
collected together in Table 2. 
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Figure 15 TH positive cells and aSyn oligomers in the SN, striatal extracellular DA, and tissue 
concentrations of DA, its metabolites and GABA in wild-type (wt) and PREPko mice that 
received supranigral injection of AAV-aSyn or co-injection of AAV-aSyn and AAV-PREP. TH+ 
cells were decreased in the SN of aSyn+PREP injected wild-type and PREPko mice compared 
to aSyn injected wild-type and PREPko mice (A). Number of aSyn oligomer particles (B) and 
extracellular DA concentration (C) were similar in all groups. Overexpression of aSyn 
decreased striatal DA concentration in all other groups except aSyn+PREP co-injected 
PREPko mice (D) but DOPAC was elevated only in this group (E). Tissue concentrations of 
HVA (F) and GABA (D) were not altered. n = 6-9. Bars represent mean ± SEM. **p < 0.01, 
two-way ANOVA (A-C) or one-way ANOVA with Tukey´s post-hoc test (D-G). 
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Figure 16 TH and total aSyn in wild-type (wt) and PREPko mice that received supranigral 
injection of AAV-aSyn or co-injection of AAV-aSyn and AAV-PREP. OD of aSyn was not 
changed statistically significantly in the STR (A), SNpc (B) or SNpr (C) but there was a trend 
for decreased aSyn in the SNpr of PREPko mice that received aSyn+PREP co-injection (C). 
TH+ fibers in the STR (D) and SNpc (E) were not changed but there was a minor decrease of 
TH+ fiber density in PREPko mice that received aSyn+PREP co-injection that correlated with 
the TH+ cell count in Figure 15. Representative brain sections from the STR and SN (G). n = 
7-8. Bars represent mean ± SEM, two-way ANOVA. 
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Table 2. The main findings of the effect of PREP on DAergic 
neurotransmission. 
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6 DISCUSSION 
6.1 THE ROLE OF PREP IN THE REGULATION  OF 
DOPAMINE TRANSPORTER PHOSPHORYLATION 
AND FUNCTION (I, II) 
PREP has been suggested to participate in the regulation of midbrain DAergic 
function for the first time when PREP inhibitor S-17092 treatment showed 
beneficial effects on the cognitive behavior of MPTP-treated monkeys, but the 
function of the nigrostriatal DAergic system was not studied (Schneider et al. 
2002). Thereafter, PREP has been shown to participate in the regulation of 
nigrostriatal DAergic function in the mouse and rat brain (Jalkanen et al. 
2012, Savolainen et al. 2014). PREP inhibitor treatment has been shown to 
modulate extracellular DA concentration in the rat STR (Jalkanen et al. 2012), 
and tissue concentration of DA and its metabolites in the STR of aSyn 
transgenic mice (Savolainen et al. 2014). PREP inhibitor KYP-2047 was also 
able to decrease immunoreactive DAT in the STR of transgenic mice 
(Savolainen et al. 2014) indicating that PREP could regulate DAergic 
neurotransmission by modulating DAT function. Based on these findings we 
decided to characterize the role of PREP in the nigrostriatal DAergic pathway 
further. Since PREP inhibitors have shown beneficial effects on aSyn 
aggregation in in vitro and in vivo models of PD (Savolainen et al. 2014, 
Myöhänen et al. 2012), we wanted to investigate if PREP inhibitor treatment 
could have a neuroprotective effect on the DAergic neurons in PD models. 
In study I, the role of PREP in DAT function was characterized in DAT 
transfected wild-type and PREPko HEK-293 cells, and, in study II, in PREPko 
mice and wild-type littermates. The effect of PREP overexpression or 
restoration of PREP expression was also studied in wild-type and PREPko 
mice that received supranigral microinjection of AAV-PREP, and in cells that 
were transfected with a combination of DAT and PREP. AAV-GFP was injected 
to the control mice, but it turned out that AAV-GFP was not an optimal control 
viral vector since it showed some toxicity in the behavioral tests in study II. 
AAV-GFP-induced toxicity has also been reported by other research groups 
(Albert et al. 2018, Landeck et al. 2017, Andersen et al. 2018), and GFP-
induced toxicity could have been avoided by using an empty vector as a control 
(Andersen et al. 2018). 
6.1.1 PKC AND ERK IN PREP-MEDIATED REGULATION OF 
DOPAMINE TRANSPORTER (I) 
PKC-mediated internalization is one of the main regulatory mechanisms for 
DAT function (Vaughan et al. 1997, Pristupa et al. 1998). PKC is able to 
phosphorylate and activate ERK, and PREP participates in the regulation of 
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ERK phosphorylation (Moreno-Baylach et al. 2011, Tenorio-Laranga et al. 
2013) indicating that PREP could possibly regulate DAT function via an ERK- 
and PKC-mediated mechanism. We studied the role of ERK in DAT 
transfected wild-type and stable PREPko HEK-293 cells to investigate if lack 
of PREP, or overexpression, inhibition or restoration of PREP function has an 
effect on ERK and DAT phosphorylation and if PREP-mediated DAT 
phosphorylation is dependent on phosphorylation of ERK. The role of PKC 
was evaluated by measuring DAT and ERK phosphorylation by Western 
blotting after PREP inhibitor treatment without and in combination with PKC 
activators and inhibitors, and by measuring PKC activity. 
The pDAT antibody used in this study detects the Thr53 phosphorylation 
site of DAT in the MAPK/SH3 domain (Foster et al. 2012) which is 
phosphorylated by not only ERK but also other MAPKs (Gorentla et al. 2009). 
Thr53 phosphorylation has been shown to regulate kinetics of DAT function 
by stabilizing DAT on the plasma membrane and increasing uptake of DA 
(Challasivakanaka et al. 2017, Foster et al. 2012, Gorentla et al. 2009). 
Surprisingly, deletion of PREP had a trend to increase the phosphorylation of 
the Thr53 site, although ERK phosphorylation and DA uptake were not 
significantly changed in study I. This suggests that PREP-regulated 
phosphorylation of Thr53 is not mediated by activation of ERK. Interestingly, 
amphetamines have a similar effect on DAT since they also promote 
internalization of DAT even though they induce phosphorylation of Thr53 
(Challasivakanaka et al. 2012, Challasivakanaka et al. 2017). Additionally, the 
effect of PREP on DAT function was not observed in the 3H-DA uptake assay 
even though phosphorylation of Thr53 has been shown to increase plasma 
membrane localization of DAT and increase DA uptake (Foster et al. 2012). 
Overall, the differences were small in the DA uptake assay suggesting that DAT 
function was impaired in all groups which was probably caused by the low 
plasma membrane localization of DAT observed in the immunofluorescence 
staining. On the other hand, one possibility is that the pDAT antibody also 
recognizes other phosphorylation sites of DAT than the Thr53 site, which 
could provide an explanation to the increased phosphorylation of DAT by PKC 
activator in study I. Consequently, these findings suggest that PREP also 
regulates DAT function with some other mechanism at the same time with 
Thr53 phosphorylation. Other possible mechanisms could be e.g. modulation 
of other phosphorylation sites or PP2A-mediated mechanisms since PREP has 
been shown to regulate PP2A activity (Svarcbahs 2019) and PP2A has been 
shown to participate in regulation of DAT (Yang et al. 2018). Measuring 
phosphorylation of the PKC domain and the CaMKII domain located 
phosphorylation sites of DAT would have provided more information of PREP-
mediated DAT phosphorylation and internalization mechanisms, but there 
were not sufficient antibodies available for those phosphorylation sites. 
Additionally, regulation of other post-translational modifications, such as 
palmitoylation, ubiquitination, and glycocylation, could be possible 
mechanisms in PREP-mediated regulation of DAT function. 
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Taken together, our studies proved the interaction between PREP and 
DAT, but since the regulation of DAT by PREP is not dependent on PKC and 
ERK, unlike predicted, the mechanism of PREP-mediated regulation needs to 
be studied further. 
6.1.2 REGULATION OF DOPAMINERGIC SIGNALING BY PREP IN 
VIVO (II) 
In study II, the striatal DAergic function of PREPko mice was studied by no-
net-flux microdialysis, fast-scan cyclic voltammetry, and Western blotting 
analysis of TH and DAT. Elevated extracellular DA level and delayed DA 
uptake in the STR of PREPko mice pointed to reduced re-uptake of DA by DAT 
in PREPko mice. Increased Thr53 phosphorylation of DAT suggested changes 
in DAT function as well. Similar results of DAT phosphorylation and function 
were observed in the cellular experiments in study I, verifying that 
phosphorylation of the Thr53 site of DAT correlates with internalization and 
reduction of DAT-mediated DA transport even though previous studies have 
shown the opposite result: that Thr53 phosphorylation is stabilizing DAT on 
the plasma membrane (Foster et al. 2012). Additionally, nigrostriatal PREP 
overexpression induced a decrease in Thr53 phosphorylation which also 
confirms that PREP regulates the phosphorylation. 
Elevated TH expression in the SN of PREPko mice indicates possibly 
increased DA synthesis, but DA synthesis by TH is also dependent on TH 
activity, not only TH expression level, and TH activity was not measured in our 
study. Phosphorylation of TH is the main regulator for its activity (Ramsey et 
al. 1996), and aSyn is able to reduce TH activity by regulating the methylation 
of PP2A (Perez et al. 2002, Peng et al. 2005, Hua et al. 2015). Since PREP has 
been shown to interact directly with PP2A and regulate its activity (Svarcbahs 
2019), PREP could possibly modify TH activity by modulating PP2A. PP2A 
also dephosphorylates recently found phosphorylation site Thr48 of DAT 
which upregulates DAT function (Yang et al. 2018) suggesting that PREP 
could also modulate DAT activity via PP2A.  
6.2 THE EFFECT OF PREP DELETION AND INHIBITION 
ON α-SYNUCLEIN-INDUCED CHANGES IN 
DOPAMINERGIC SIGNALING (I, III, IV) 
aSyn regulates DAergic neurotransmission via several mechanisms by 
modulating DA synthesis, storage, release, and metabolism (Butler et al. 
2017). Several studies have shown that aSyn interacts with DAT by direct 
binding (Lee et al. 2001, Wersinger & Sidhu 2003), but also through other 
mechanisms. However, there have been controversial results as to whether 
aSyn stabilizes DAT on the plasma membrane (Lee et al. 2001, Butler et al. 
2015) or induces its internalization (Oaks et al. 2013, Kisos et al. 2014, Swant 
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et al. 2011, Pelkonen et al. 2013). PREP directly interacts with aSyn and 
regulates its aggregation and oligomerization in cells (Brandt et al. 2008, 
Dokleja et al. 2014) and in transgenic mice (Myöhänen et al. 2012, Savolainen 
et al. 2014). Since studies I and II showed that PREP participates in the 
regulation of DAergic neurotransmission, we wanted to study if aSyn is able to 
modulate the effect of PREP on DAergic function. Additionally, we studied if 
PREP inhibition, lack of PREP or restoring PREP function modify the effect of 
aSyn overexpression in cells in study I and in the nigrostriatal DAergic 
pathway of mouse in studies III and IV. The effect of PREP inhibitor treatment 
was studied in aSyn overexpression model of PD in study III. 
6.2.1 α-SYNUCLEIN AND PREP IN REGULATION OF DOPAMINE 
TRANSPORTER PHOSPHORYLATION IN CELLS (I) 
aSyn regulates DAT function by direct binding to the N-terminal of DAT (Lee 
et al. 2001), but aSyn also inhibits PKC activity (Ostrerova et al. 1999) 
suggesting that aSyn could possibly regulate DAT phosphorylation via PKC. 
Since PKC activates ERK, the interaction between aSyn and PKC could affect 
phosphorylation of ERK and DAT. However, we did not observe aSyn-induced 
alteration in phosphorylation of DAT or ERK in wild-type HEK-293 cells in 
study I, but aSyn and combination of aSyn and PREP lowered phosphorylation 
of DAT in the PREPko cells in the Western blotting experiment. However, 
phosphorylation of ERK was not changed suggesting that aSyn is, similar to 
PREP, able to modulate phosphorylation of the Thr53 site of DAT independent 
from ERK phosphorylation even though ERK is known to phosphorylate the 
Thr53 site at least in vitro (Gorentla et al. 2009).  
aSyn overexpression reduces PKC activity (Ostrerova et al. 1999) 
suggesting that it could reduce phosphorylation of the PKC domain of DAT 
which could decrease internalization of DAT and increase DA uptake. 
Nevertheless, phosphorylation of the Thr53 site has the opposite effect 
(Challasivakanaka et al. 2017, Foster et al. 2012). A mild decrease in DAT 
function in a DA uptake assay in aSyn and in aSyn+PREP transfected cells 
correlates with Thr53 phosphorylation of DAT. This is in line with the previous 
study showing Thr53 phosphorylation increasing plasma membrane 
localization of DAT (Foster et al. 2012), but opposite to the findings with naïve 
PREPko cells and PREPko mice in studies I and II. This indicates that although 
both aSyn and PREP regulate Thr53 phosphorylation of DAT, there are also 
other simultaneous mechanisms in PREP- and aSyn-mediated regulation of 
DAT function and localization. 
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6.2.2 PREP INHIBITOR TREATMENT RESTORES NIGROSTRIATAL 
DOPAMINERGIC FUNCTION IN MOUSE MODEL OF 
PARKINSON´S DISEASE (III) 
aSyn overexpression induced by supranigral injection of AAV-aSyn 
significantly reduced extracellular DA, tissue concentration of DA, and TH 
immunoreactivity in the STR and SN which is in line with the previous studies 
of an aSyn overexpression model of PD (St Martin et al. 2007, Dong et al. 
2002, Ulusoy et al. 2010). PREP inhibitor treatment had a significant 
improvement on the behavior in the cylinder test although extracellular DA, 
tissue concentration of DA, and immunoreactive TH in the nigrostriatal 
pathway were not increased. However, the reduction of toxic aSyn oligomers 
correlated with the improved behavior. aSyn oligomers have been shown to 
impair synaptic vesicle function and SNARE-complex formation by binding to 
the lipid bilayer of the synaptic vesicles and to VAMP2 (Choi et al. 2013, Lai et 
al. 2014, DeWitt & Rhoades 2013). These interactions are able to reduce DA 
release from the presynaptic vesicles to the synaptic cleft. PREP inhibitor-
induced reduction of oligomers could possibly enhance DA storage and release 
by normalizing synaptic vesicle function and SNARE-complex assembly 
although the extracellular or tissue concentration of DA had not been 
recovered. aSyn overexpression caused only a minor loss of TH+ neurons thus 
recovery on neuronal loss is probably not needed to repair the behavioral 
deficit and DAergic function. A similar phenomenon has also been observed 
earlier by another research group when aSyn overexpression caused impaired 
behavior in cylinder test and amphetamine-induced and apomorphine-
induced rotation tests but only a mild loss of DA neurons (Gaugler et al. 2012). 
They found aSyn-induced depletion of synaptic vesicles in DAergic axons by 
quantitative ultrastructural analysis, and reduction in depolarization-induced 
DA release by amperometric recording, indicating that impaired DA release in 
the STR has a more remarkable role in behavioral deficits than neuronal cell 
loss (Gaugler et al. 2012). Our similar results indicate that there are similar 
mechanisms in PREP inhibitor-mediated restoration of DAergic function and 
behavior. 
Autophagy induction reduces DA release by decreasing DA containing 
synaptic vesicles (Hernandez et al. 2012, Limanaqi et al. 2018), and PREP 
inhibition is able to induce autophagy (Savolainen et al. 2014) suggesting that 
PREP inhibition could decrease DA release by autophagy induction. Reduced 
DA in the presynaptic terminals could also decrease DA-induced oxidative 
stress and reduce toxicity and cell loss. 
6.2.3 DELETION OF PREP PROTECTS FROM α-SYNUCLEIN INDUCED 
TOXICITY IN MICE (IV) 
Although extracellular DA concentration was significantly reduced in the naïve 
PREPko mice compared to wild-type littermates in study II, a similar 
difference was not observed in the AAV-aSyn injected STR regardless of 
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absence, presence, overexpression or restoration of PREP in study IV. PREP 
was shown to modulate extracellular DA level by controlling DAT function 
without aSyn overexpression, but an excessive amount of aSyn probably has a 
greater influence on DAT function than PREP since aSyn directly binds to DAT 
(Lee et al. 2001) and also modulates other regulators of DAT function (Butler 
et al. 2017). Also, the cellular experiments in study I showed that in the 
presence of aSyn PREP does not have a significant effect on the DAT function. 
Deletion of PREP protected mice from behavioral changes in the locomotor 
activity test and in the cylinder test suggesting that lack of PREP could have a 
similar protective mechanism as PREP inhibitor treatment. Since extracellular 
and tissue concentration of DA were not significantly different, the harmful 
effect of aSyn and combination of aSyn+PREP in wild-type mice could be 
caused by aSyn-induced reduction in DA storage vesicles and DA release (Choi 
et al. 2013, DeWitt & Rhoades 2013). Deletion of PREP prevented aSyn-
induced behavioral deficits suggesting that PREP is needed for aSyn-induced 
impairment of DA storage and release. Although, restoration of PREP 
expression to PREPko mice did not cause behavioral changes in the cylinder 
test indicating some compensative mechanisms in PREPko mice. 
 
 
Figure 17 PREP-regulated functions in DAergic signaling. 1. Lack of PREP increased TH in the 
mouse SN indicating that PREP could decrease DA synthesis by decreasing TH. 2. PREP 
inhibition and deletion were able to normalize aSyn-induced impairment of DA release and 
SNARE-complex assembly in mouse brain. 3. PREP regulated DAT function by modulating 
phosphorylation and internalization of DAT in cells and in vivo. 
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Altogether, aSyn-induced changes in DAT function, DA storage, and DA 
release seem to cover possible PREP-mediated changes in DAT function. The 
effect of PREP inhibition on aSyn in study III appears to be different from the 
effect of deletion of PREP in study IV. Additionally, in study II PREP inhibition 
failed to produce a similar effect on DAT function as PREP deletion. These 
findings indicate that there might be compensative mechanisms in PREPko 
animals and in PREPko cells. Only PREP inhibitor KYP-2047 was used in the 
studies but other inhibitors could possibly have different effects on DAergic 
function since protein-protein interactions of PREP are not dependent on 
PREP enzyme inhibition (Savolainen et al. 2015, Svarcbahs 2019). PREP-
regulated functions DAergic signaling have been presented in Figure 17. 
6.3 FUTURE DIRECTIONS AND SUMMARY OF 
DISCUSSION 
Our studies have shown that PREP certainly has a role in the regulation of the 
nigrostriatal DAergic system but the mechanisms behind these findings needs 
to be studied further to be able to utilize the findings in the treatment of PD 
and other neurodegenerative diseases. Studies III and IV are suggesting that 
the lack of PREP and PREP inhibition could enhance or restore DA recycling, 
but this was not measured directly. This could be confirmed for example by 
measuring density and number of DAergic vesicles in the nerve terminals by 
quantitative ultrastructural analysis (Gaugler et al. 2012) to be able to claim 
that PREP inhibitor treatment could be beneficial for DAergic function in PD. 
Study I revealed that PREP-mediated regulation of DAT is independent of 
ERK and PKC but the actual mechanism has still remained obscure, creating 
a need for further studies to discover the mechanism. PREP has been shown 
to regulate PP2A (Svarcbahs 2019) which participates in the regulation of DAT 
(Yang et al. 2018), suggesting that PREP could regulate DAT via a PP2A-
mediated mechanism, but this has not yet been studied. There are also 
numerous other possible targets for PREP-mediated regulation of DAT 
function if the mechanism appears to be independent from PP2A.  
If the PREP-mediated mechanisms in DA recycling and in regulation of 
DAT can be clarified, PREP inhibitors could provide a novel possibility to treat 
PD. An advantage in PREP inhibitor-based treatment is that in addition to 
enhancing dopaminergic function, it can also accelerate autophagy and 
enhance clearance of aSyn aggregates (Savolainen et al. 2014, Svarcbahs 
2019), thus making it a multi-target treatment which could modify the 
progress of PD. This would be an exceptional advancement in the treatment of 
PD since current medications relieve symptoms, but they are not able to slow 
or stop the progression of PD. However, it still requires years of preclinical and 
clinical studies to confirm if PREP inhibitors could have a clinical potential to 
treat PD or other neurodegenerative diseases. 
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There has been debate on the role of aSyn in the pathophysiology of PD 
since some studies have shown that aSyn aggregates and Lewy bodies are non-
toxic to the neurons, and Lewy bodies are also found in neurologically normal 
brains (Parkkinen et al. 2005). It has been suggested that aSyn could be an 
innocent by-stander, and some other mechanism is the main reason for 
neurodegeneration in PD. However, the role of aSyn in regulation of DAergic 
homeostasis indicates that misfolded aSyn disturbs normal DAergic function 
and there are numerous studies showing that oligomeric aSyn has toxic 
properties (Bengoa-Vergniory et al. 2017). PD-linked mutations in SNCA gene 
are also a strong statement for the importance of aSyn in PD pathophysiology. 
Therefore, the central role of aSyn does not rule out the possibility for some 
other fundamental mechanisms in the pathophysiology of PD. 
In addition to PREP inhibitors, there are also other aSyn-targeting 
treatments that are already in clinical trials. A broad-based tyrosine kinase 
inhibitor, nilotinib, reverses DAergic cell loss and restores motor function by 
inducing autophagic degradation of aSyn in preclinical models of PD (Hebron 
et al. 2013), and phase I clinical studies have had promising results (Pagan et 
al. 2019). Additionally, aSyn antibody treatments have been able to rescue 
DAergic cells and improve behavior in animal models of PD (Masliah et al. 
2005, Games et al. 2014), and they also have been safe in phase I clinical trials 
(Schenk et al. 2017). However, phase II clinical trials of aSyn-targeted 
therapies have not been published so far. If PREP inhibitors or other aSyn-
targeted treatments appear to be an effective and safe way to treat PD in the 
future, they could be the first disease-modifying treatments for PD which 
could revolutionize the lives of millions of PD patients around the world. 
PD is becoming increasingly common since the population is ageing and 
the duration of the disease has also become longer (Dorsey et al. 2018). 
Additionally, prevalence of PD has been increasing faster than the prevalence 
of any other neurodegenerative disease in the world. The long duration and 
the progressive disabling nature of the disease also makes it extremely 
expensive for society, and it is also important to remember the heavy burden 
of the disease for an individual patient. This situation creates an emerging 
need for new and more effective treatments for PD. 
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7 CONCLUSIONS 
The aim of the study was to characterize the role of PREP and aSyn in DAergic 
neurotransmission in the nigrostriatal pathway. The role of PREP was studied 
by comparing DAergic function of PREPko cells and PREPko mice. The effect 
of PREP inhibitor treatment was investigated in an aSyn overexpression model 
of PD and the role of aSyn was studied in transfected cells and in AAV-injected 
mice. The main conclusions were: 
 
I PREP regulated DAT phosphorylation and function in transfected 
HEK-293 cells and in the mouse STR, but the mechanism was 
independent from PKC and ERK activation. 
II PREP inhibitor KYP-2047 treatment restored DAergic function and 
behavior by decreasing aSyn oligomers, but it did not have a 
significant effect on the nigrostriatal DA level in an aSyn 
overexpression model of PD. 
III Lack of PREP protected from AAV-aSyn-induced toxicity in the 
behavioral test although tissue concentration of DA was decreased and 
the extracellular DA was not altered.  
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